Form 10KSB

10KSB 1 nvid10ksb.htm Form 10KSB

U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-KSB

(Mark One)

[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

For the fiscal year ended December 31, 2000

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934

For the transition period from ________ to __________

Commission file number 0-30936

NVID INTERNATIONAL, INC.
(Name Of Small Business Issuer In Its Charter)

DELAWARE 59-3458195
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification No.)

28163 U.S. Highway 19 North, Suite 302,
Clearwater, Florida 33761
(Address Of Principal Executive Offices) (Zip Code)

(727) 669-5005
(Registrant's Telephone Number, Including Area Code)

Securities registered under Section 12(b) of the Exchange Act:

NONE

Securities registered under Section 12(g) of the Exchange Act:

Common Stock, par value $0.001

Check whether the issuer (1)filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes No X

Check if there is no disclosure of delinquent filers in response to Item 405 of
Regulation S-B is not contained in this form, and no disclosure will be
contained, to the best of registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-KSB
or any amendment to this Form 10-KSB. [ ]

State issuer's revenues for its most recent fiscal year. $12,588

State the aggregate market value of the voting and non-voting common equity held
by non-affiliates computed by reference to the price at which the common equity
was sold, or the average bid and asked price of such common equity, as of April
6, 2001. $5,663,730

(APPLICABLE ONLY TO CORPORATE REGISTRANTS)

State the number of shares outstanding of each of the issuer's classes of common
equity, as of April 6, 2001. 67,197,118

DOCUMENTS INCORPORATED BY REFERENCE

If the following documents are incorporated by reference, briefly describe them
and identify the part of the Form 10-KSB (e.g., Part I, Part II, etc.) into
which the document is incorporated: (1) any annual report to security holders;
(2) any proxy or information statement; and (3) any prospectus filed pursuant to
Rule 424(b) or (c) of the Securities Act of 1933 ("Securities Act"). The list
documents should be clearly described for identification purposes (e.g., annual
report to security holders for fiscal year ended December 24, 1990). NONE

Transitional Small Business Disclosure Format (check one):

Yes No X

PART I

Item 1. Business.

General

NVID International, Inc. (the "Company") is a holding company the sole
material asset of which is the stock of its subsidiary, Aqua Bio Technologies,
Inc. References to the Company in this registration statement include the
activities of its subsidiary. The Company is in the business of researching,
developing and marketing water purification and disinfection products using a
technology known as ionization.

The Company was incorporated on August 20, 1984 under Delaware law as
Network Video, Inc., for the purpose of franchising video specialty stores. In
1986, it completed an initial public offering pursuant to a Registration
Statement under the Securities Act of 1933 on Form S-18. On February 17, 1988,
the Company filed Form 15, terminating its obligation to file periodic reports
with the United States Securities and Exchange Commission (the "Commission").
The Company discontinued its video business in 1988 because of intense
competition.

The Company conducted no business until 1994, when it entered into an
agreement with Superior Aqua Products, Inc., a Florida corporation ("Superior").
Under that agreement, the Company acquired all of the outstanding shares of
Superior in exchange for the issuance of 18,281,500 shares of its common stock.
At the same time, the Company's shareholders authorized its name change to NVID
International, Inc.

The Company's administrative office is located at 28163 U.S. Highway 19
North, Suite 302, Clearwater, Florida 33761, and its telephone number is (727)
669-5005. The Company's fiscal year end is December 31.

On April 4, 1997, the Company was named as a defendant in civil
litigation brought by the Commission stemming from the actions of two Company
officers arrested for misappropriation of stockholder funds and fraud. On April
5, 1997, the two officers and two additional members of the Company's board of
directors resigned from their positions with the Company. On April 15, 1998,
following negotiations between the Company's new management and the Commission,
the Company executed a Consent and Stipulation for Final Judgment, which was
approved on August 14, 1998, and which terminated the Commission's proceedings
against the Company.

The terms of the Consent and Stipulation for Final Judgment included a
full settlement, without adjudication of any facts or law, in which NVID agreed
to pay a fine and prejudgment interest; all but $25,000 of the fine and interest
was waived following NVID's transfer of certain assets to a court-appointed
receiver for distribution to investors. No other civil penalty was imposed on

NVID. NVID also voluntarily consented to the entry of a Final Judgment of
Permanent Injunction and Other Equitable Relief, and waived any rights it might
have had to the assets of the two former officers named as co-defendants.
Finally, NVID agreed to cancel any NVID shares owned by the former officers and
a former director. The Company's current management has no relationship with the
officers and directors who resigned on April 5, 1997.

Company History

When current management took control of the Company in April 1997, the
Company had just been named as a defendant in the civil litigation brought by
the Commission. All Company assets were frozen at this time, and the Company
did no substantive business until August 14, 1998, when current management
executed the Consent and Stipulation for Final Judgment.

Prior to April 4, 1997, when the Company's assets were officially
frozen, the Company's product sales were made through a network of approximately
fifteen independent dealers and distributors, each of which generally carried
only one product line. Despite the existence of a network of independent
dealers, the Company's sales prior to April 4, 1997 were insignificant. During
the litigation by the Commission, which lasted over a year, all but two dealers
closed their businesses. Management's focus necessarily remained on resolving
the litigation favorably and bringing the Company forward. During this period,
the total number of Company employees was reduced from fourteen to two. The
Company currently has only two employees, both of whom work for the Company
full-time.

At the time of the litigation, the Company was developing a new product
called Axenohl - a non-toxic, stabilized form of ionic copper concentrate, which
can be used as an additive in hard-surface disinfectants. Tests performed for
the Company by ABC Research, Inc. of Gainesville, Florida showed encouraging
results for copper solutions, but significantly better results when silver
electrodes were used to create the ionic solution, instead of copper electrodes.
In fact, the efficacy produced by the silver ionic solution in Axenohl convinced
the Company to substitute silver for copper in most of its ionization products.
Axenohl's development was a milestone in the Company's history, because it
changed the Company's focus in ionization from copper to silver, and opened an
array of potential markets and applications for the Company's products.

Since the Commission terminated the litigation, the Company's principal
focus has been testing, researching and developing its water purification and
disinfection product lines. Other than a few pool and spa products, since April
1997, the Company's minimal revenues have been comprised of sales incidental to
research and testing of the Company's products. The Company has pursued U.S. and
worldwide patent protection for its products, has sought to qualify for certain
government and regulatory certifications and permits and has nearly completed
the infrastructure necessary to bring its products to market.

Company's Current Activities

The Company's efforts continue to focus on the research and development
of its water disinfection product lines and the creation of a network of
licensed distributors to sell its products. The Company's product lines include
(i) three separate ionization water purification systems: Superior Aqua Systems
("SAS"), Ionic Disinfection Systems ("IDS"), and Random Metering System ("RMS"),
and (ii) the hard-surface disinfectant, Axenohl. All of these products are fully
developed and available for purchase from the Company or one of its licensed
distributors. The Company has focused on a marketing approach designed to
license corporate partners to sell the Company's products for specific
applications, including: (i) pool and spa disinfection, (ii) industrial and
residential water purification and (iii) agricultural aspects of water
disinfection. Currently, the Company has signed license agreements with four (4)
corporate partners:

1.) Innovative Medical Services On November 24, 1999, the Company
entered into a three year license agreement with Innovative Medical
Services ("IMS") for the distribution and sale of Axenohl for
specific geographic and market segments. IMS may market Axenohl in
the Point of Use/Point-of-Entry, Healthcare, Food Processing and Dental
Markets in certain described, geographic territories. The license includes
an automatic renewal for an additional three-year term. To the extent
that amounts are paid to the Company under this Agreement, the Company
is obliged to pay 2.5% of such amounts to Dr. Charles Lewis as compensation
for introducing the Company and IMS.

2.) ETI-H20, Inc. On November 30, 1998, the Company entered a five-year
Standard Manufacturing Agreement with ETI-H20, Inc. ("ETI-H20").
Pursuant to the agreement, ETI-H20 may manufacture and sell Axenohl
exclusively in the Southeastern United States (Florida, Georgia,
Alabama, Mississippi, Louisiana, South Carolina, North Carolina,
Virginia, Tennessee and Kentucky) and Costa Rica. NVID will receive
a royalty of 15% of the gross price for all product sold in these
territories after December 5, 2000. NVID also has the option of
buying out ETI-H20's rights under the agreement at any time.

The Company also entered a two-year Standard Manufacturing Agreement
(Pacific Rim Countries) with ETI-H20 on September 17, 1999. This
agreement, however, was subject to certain performance criteria that
the Company believes will not be met before the license expires
September 16, 2001.

3.) Watertronics, Ltd. A license agreement for the distribution
and manufacturing of Axenohl in the United Kingdom was executed December
14, 1998 between the Company and Watertronics, Ltd. The license agreement

has a five (5) year term with automatic renewals subject to certain
performance criteria.

4.) Aqua Bio Technologies, S.A. de C.V. A license agreement was executed
March 5, 2000 between the Company and Federico Rodriguez, a
principal and officer of Aqua Bio Technologies, S.A. de C.V., for
the exclusive distribution of Axenohl in Mexico. The March 5, 2000
license agreement augments a distribution agreement between the
Company and Aqua Bio Technologies S.A. de C.V. dated March 5, 2000
for the distribution and sale of the Company's RMS, IDS and SAS
product lines in Mexico.

The Company is also establishing a distributor network and expects to
sell directly to large institutional and governmental entities via direct sales
and e-commerce. The Company's website can be found at www.aquabiotech.com.

The Company has no additional products under development, but it is
conducting further studies aimed at identifying additional market applications
for the Company's existing product lines. Most of these additional applications
focus on the agricultural industry, which the Company believes is one of the
water disinfection and purification markets with the largest growth potential.
For example, the Company is developing a disinfection system for poultry
applications and is researching the application of Axenohl for reducing blight
infection on agave cactus.

The Company has a small asset base of $724,093, the majority of which
are intangible assets. Although the Company has been in existence for a number
of years, management's efforts to develop the Company's business have not yet
resulted in generation of significant revenues. Indeed, the Company has
experienced net losses of $578,500 in 1998, $793,137 in 1999 and $872,932 in
2000. It has an accumulated deficit of $6,818,381 as of December 31, 2000.
As noted in the report of its independent certified public accountants, the
Company's operating losses raise substantial doubt about its ability to continue
as a going concern.

To date, management's efforts have focused on developing licensing
relationships and promoting and conducting research and development to
demonstrate the feasibility and efficacy of the Company's products. Until
potential customers are convinced of the viability of the Company's technology,
it is unlikely that the Company will generate significant revenue.

Overview of Business

The Company develops water disinfection systems that use "ionization."
These systems are based on a process that emits precise amounts of copper and
silver ions into water systems to control and remove bacteria, viruses, fungi,

yeast and algae. Uses for the Company's products include industrial, commercial
and residential water systems, cisterns, hospitals, agriculture, marine habitats,
pools, fountains, spas and cooling towers. From simple applications like pools,
spas or fountains, to more complicated hospital infection control systems, the
Company's products are designed to meet a broad spectrum of water disinfection
requirements. In addition to water disinfection systems, the Company owns the patent
rights to Axenohl through assignment. Axenohol is a non-toxic, environmentally
friendly liquid disinfectant, formulated for initial use as a hard surface cleaner.
Axenohl is also produced with proprietary ionization technology.

There are various technologies used for disinfecting water. The
conventional technologies include chlorine, reverse osmosis, filtration,
ultraviolet light, ozone and chlorine dioxide. While all of these technologies
have beneficial attributes, they also possess significant drawbacks in terms of
cost, ease of handling and use, maintenance and long-term disinfecting capability
(commonly referred to as "residual effect"). In addition, conventional water
treatment systems often use significant amounts of chlorine, a highly toxic and
caustic chemical. Repeated studies have shown that the toxicity of chlorine
creates dangerous health and environmental hazards and is caustic to equipment.

The benefits of the Company's ionization products include reduced
operating and maintenance costs resulting from a reduction of chlorine and
increased life of operating equipment.

Silver and copper have long been known for their biocidal properties -
copper for its ability to kill algae, and silver for its ability to kill a wide
range of bacteria and viruses. In fact, the characteristics of the process now
known as "ionization" were recognized in ancient Greece, where copper cups and
silver chalices were the preferred way to store drinking water. During the 19th
century, pioneers in the United States placed copper and silver coins in the
water casks attached to their wagons. The constant rocking and rolling of the
wagons released ions of copper and silver, which killed bacteria, yeast and
viruses, and helped maintain a clean water supply. More recently, NASA used
ionization technology to control bacteria for the Apollo space missions.

Ionization begins when an electric charge is applied to specially
formulated alloys of copper or silver. When electricity contacts the alloy, an
electrically charged atom called an "ion" is released. Ions, which have a
positive charge, attach to algae walls, bacteria and other particles, which have
a negative charge. The ions penetrate the foreign substances' membranes, and
eventually the foreign substances die. In killing the algae or bacteria, the ions
function much the same way as white corpuscles in the bloodstream. They attack
and kill by attaching themselves to the cells' membranes. The dead matter then
clumps together and is carried away and filtered out of the water. Ionization is
a safe and effective method of removing bacteria and algae from water, while
avoiding the harmful side effects caused by large doses of chlorine or other
conventional water treatment chemicals.

All water systems are susceptible to growth of microorganisms. Colonies
of microorganisms, including bacteria, viruses, protozoa and fungi, usually grow
within pipes, plants and tanks. Algae may also be present if the microorganisms
are exposed to sunlight. Sloughing, water pressure and grazing by protozoa release
the microorganisms into the water, where they can damage pipes and, more seriously,
expose water users to harmful - even fatal - bacteria (such as the bacteria known
as Legionella Pneumophila ("Legionella"), responsible for Legionnaire's Disease).
Chemical treatments, dosed at "safe" levels, are often unable to cope with the
freed bacteria in the time available for treatment. The Company believes that
ionization is gaining recognition as the most successful and cost-effective
method of preventing the proliferation of microorganisms with minimal
environmental impact.

Industry Overview

Water purification and disinfection is a multi-billion dollar global
industry because of an increasingly limited supply of drinkable water, global
economic expansion, the increasing need for high-quality or ultra pure water by
commercial and industrial companies, heightened public health and safety concerns
relating to drinking water, and the promulgation of numerous government regulations
for water quality. Management believes that water contamination is one of the
world's most serious environmental risks.

The Company believes that it has benefited from, and will benefit from,
several existing and emerging market trends, including increased consumer emphasis
on health and safety concerns relating to drinking water and water supplies,
growing demand for alternatives to chlorine-based systems and continued promulgation
of government regulations relating to water purification and treatment.

Principal components of the water purification and disinfection industry
include the consumer, bottled water, commercial and industrial, residential/
municipal drinking water and wastewater treatment markets. With the exception of
bottled water, the Company has developed products, which meet the needs of
consumers in each of these market segments. Specifically, the Company has focused
on applications for Legionella control within hospital hot water systems, cooling
tower disinfection, industrial and residential drinking water disinfection and
purification, horticultural aspects of disinfection, pool and spa disinfection,
dental waterline disinfection and hard surface disinfection within the food
processing industry.

Disinfection/Purification Technologies

The principal technologies used in the water disinfection and purification
industry include:

Filtration. Filtration is a process typically used for separating solids
from a liquid by means of a porous substance, layers of inert material (e.g.
sand, gravel) or a membrane. The most significant drawback to filtration is the
lack of a residual effect and the limitations imposed by the size of the filters,
which can be ineffective for controlling the growth of microorganisms.

Reverse Osmosis. Reverse osmosis is a water treatment process that
removes undesirable materials from the water by using water pressure to force
the water molecules through a semi-permeable membrane. Reverse osmosis, like
filtration, has no residual effect and can be extremely expensive because of the
replacement cost of a membrane.

Chlorine. A long-standing technology for water treatment first used
at the beginning of the 20th century, chlorine remains the most widely adopted
form of water treatment in the United States. Chlorine is a relatively inexpensive
gas, which at appropriate levels, destroys most water-borne pathogens. The
drawbacks of chlorine include its high toxicity to human health through disinfection
by-products called trihalomethanes ("THMs"), storage and handling problems,
limited residual effect, susceptibility to heat and light, and environmental concerns.

Chlorine Dioxide. Though more expensive than chlorine, chlorine dioxide
is also more stable and retains a longer disinfecting residual than chlorine.
Chlorine dioxide, however, suffers the same logistical and handling problems as
chlorine and is also highly unstable under temperature and heat fluctuations.

Ozone. Ozone, a pale, light blue gas, has been used to treat drinking
water since the end of the 19th century. Significantly more expensive than
chlorine, ozone has highly effective germicidal properties. In addition to its
cost, however, ozone cannot be stored or transported because of its short lifespan.
It has no residual effect.

Ultraviolet Light. Ultraviolet light is nominally more expensive than
chlorine, though it has no residual effect. It is effective against most forms of
viruses, though the equipment necessary for its use reduces its applications.

Ionization. Ionization disinfection systems were developed to overcome
the disadvantages and hazards associated with disinfection by chlorine and other
conventional water treatment systems. The contact time of silver, aided by the
synergistic effects of copper, will kill bacteria and viruses within minutes and
are completely unaffected by temperature and sunlight. Ionization is cost-effective,
non-corrosive, non-toxic, easily regulated and has a long-term residual effect.
As important, ionization technology is environmentally friendly and creates no
human health hazards. Ionized water produced by the Company's systems is odorless,
tasteless and, perhaps most importantly, ultra pure. The biggest drawback to
ionization is the under or over dosing which may occur with conventional ionization

equipment. The only known ionization systems that can precisely dose and meter
ions are the RMS, IDS and Axenohl concentrate (which is metered into the process
water with a conventional dosing pump). Additionally, conventional ionization
units using a high percentage of copper assayed electrodes have the potential to
stain marcite or plaster pools. For staining to occur, however, alkalinity, pH,
and calcium hardness must be extremely out of balance, and the copper ion level
must be at 1ppm or higher. As a practical matter, this would only occur if the
disinfection system was totally neglected. Significantly, even at 1ppm, the water
would not be a health hazard to humans.

The Company's Products

The selection of a particular Company water disinfection system depends
on the consumer's end-use and application. The Company's product lines include
Superior Aqua Systems, Ionic Disinfection Systems and the Random Metering System.
The Company has also developed and markets Axenohl, a liquid disinfectant formulation
that employs ionization technology. All of these products are fully developed and
available for purchase from the Company or one of its licensed distributors.

Random Metering System. Traditional ionization equipment produces the
same output rate of ions, regardless of the demands placed on the water system.
The RMS expands the application of ionization disinfection systems by creating a
separate water source to create ions outside of the treated water stream. RMS is
the only known ionization water disinfection system that can treat large volumes
of drinking water. By controlling the off-line water flow, ions can be concentrated
and injected into the treated water based on actual demand and flow rates.

Ions produced by the RMS product do not dissipate in high temperatures,
unlike competitive technologies such as chlorine. This factor is significant
because high temperatures can reduce the residual disinfection potency of a
particular water purification technology. Similarly, the residual potency of
chlorine is reduced by exposure to ultraviolet light from the sun. Ionization is
unaffected by sunlight. These characteristics enable RMS products to be used
specifically to prevent and control Legionella. The Legionella organism thrives
within colonies of microorganisms, which adhere to the inside of piping distribution
networks that transport water for domestic and drinking water use. Because RMS
can treat even large volumes of water effectively, it can be used in health care
and hospital settings.

In 1998, the Company formed an alliance with EHPC Ionization, Ltd. of
London, England, ("EHPCI, Ltd.") a company with similar interests in ionization
technology. EHPCI, Ltd. holds the exclusive license from the inventors of the RMS
system to commercialize that system. EHPCI, Ltd. has entered into a distribution
and exclusive license agreement with the Company that enables the Company to use RMS
technology to assemble, sell, distribute and service the RMS product line in North
America. The License expires on December 31, 2005.

Subsequently, with the Company's consent, EHPCI, Ltd. and Wallace & Tiernan,
a subsidiary of United States Filter Corporation, executed an agreement allowing
Wallace & Tiernan to manufacture, market and distribute the RMS technology on a
non-exclusive, global basis. Because this arrangement would infringe on the
Company's North American territory, the Company is entitled to one-half of all
licensing fees and royalties paid by Wallace & Tiernan to EHPCI, Ltd. EHPCI Ltd.
recently assigned its RMS technology rights to an affiliated company, GWR, Ltd.

In the fourth quarter of 2000, the Company executed a Stock Purchase
Agreement with the shareholders of EHPCI, Ltd. and acquired all of the issued and
outstanding shares of EHPCI, Ltd. in exchange for 2,250,000 shares of the Company's
stock. The Company is obligated to transfer an additional 750,000 shares of the
Company's stock to the selling EHPCI, Ltd. shareholders upon the occurrence of
certain conditions.

RMS is distributed and marketed in Mexico by Aqua Bio Technologies, S.A. de
C.V.

Ion Disinfection System. The IDS was designed to augment the Company's
RMS product line. IDS uses ionic silver in much the same way as the RMS system.
The differences between the RMS and IDS systems are size and dosing capabilities.
While the RMS product line is designed to treat large volumes of water with
adjustable injection of precise doses of ionic silver, the IDS unit doses directly
into the treated water at a constant rate depending on water flow. The compact size
of the IDS units makes them preferable for residential and light commercial use.
Target markets include cisterns, water wells, restaurants and small to medium sized
hotels. Because of the size and performance capabilities of the IDS product line,
IDS products have also been used in emergency situations requiring potable drinking
water.

Based on the operational success of the IDS system in Mexico, the Company
has entered into a distributor agreement with Mr. Federico Rodriguez, the owner
of Aqua Bio Technologies, S.A. de C.V. Aqua Bio Technologies, S.A. de C.V. has
been incorporated under the laws of Mexico to perform distribution and marketing
functions through its dealership arrangements with Mexican distributors.

Superior Aqua Systems. The Company's SAS product line operates in conjunction
with the existing circulation system of a pool, spa, cooling tower or hot water
system. SAS products use a flow cell, which is simply inserted into the existing
water circulation system, and a control unit, which electronically regulates the
output of ions into the water. The release of the ions maintains a long-term
disinfecting residual effect regardless of heat, sunlight or evaporation. A simple
testing kit may be used to monitor subsequent water quality. When low levels of
chlorine are used with SAS, a synergistic residual effect produces near pristine water
quality at a very low cost.

Management believes SAS is beneficial for use in indoor and outdoor pools,
fountains, decorative ponds, cooling towers and a wide range of mid-level industrial
and agricultural applications. It is cost effective, environmentally safe and user
friendly. Aqua Bio Technologies, S.A. de C.V. is the Company's licensed distributor
for SAS products in Mexico.

AXENOHL. In addition to developing and marketing ionization water treatment
systems, the Company markets the non-toxic,disinfectant product Axenohl (formerly
Microsafe). Axenohl formulations have been developed for six separate market groups:
(1)veterinary medicine, (2) healthcare, including dental applications, (3) drinking
water, (4) cooling towers, (5) hard surface disinfectant and (6) human topical.

The world market for cleaning compounds is a multi-billion dollar industry.
Cleaning products may be classified broadly as household cleaners or industrial/
institutional cleaners. Household cleaners include laundry detergents, dish
detergents and surface cleaners. Only surface cleaners are marketed typically as
having disinfectant properties.

Axenohl uses ionization stabilization technology to create a liquid
disinfectant suitable for many applications, including prevention of contamination
by bacteria and viruses. The product is formulated by generating silver ions in
an organic acid bath, which acts as a stabilizer for the silver. Axenohl can be
produced in a liquid concentrated form and used on surfaces in food processing
plants, homes, hospitals, restaurants and public facilities to kill bacteria,
viruses, and other microorganisms. Axenohl is cost effective to ship long distances
by container because of the high concentration levels achieved in the manufacturing
process. As a result, this allows the Company to market Axenohl over a broad
geographical area.

The Company licenses the Axenohl technology to corporate partners for
manufacture and sale. IMS signed a five-year license agreement to distribute and
market Axenohl for certain territories and markets. The Company has also entered
license agreements with ETI-H20 to manufacture and distribute Axenohl in the
southeastern United States, Costa Rica and selected countries in southeast Asia.
Further research and refinement of the Axenohl product is being conducted by Bio
Analytical Services, Inc., Key Laboratories and ABC Research, Inc., among others.

Manufacture, Distribution and Sale of Products

The Company distributes its products by licensing them for manufacture,
distribution and sale. Currently, the Company's RMS and IDS products are
manufactured exclusively by Westlund Engineering, Inc. of Clearwater, Florida.
The Company's SAS product line is manufactured by Superior Aqua Enterprises, Inc.

of Sarasota, Florida. Axenohl is manufactured for the Company by ETI-H20 of Lake City,
Florida. Current licensing arrangements provide a distribution network for the
Company's products encompassing both domestic and international markets, including
North America, the United Kingdom, Mexico, Central and South America and Southeast
Asia.

The Company's water disinfection systems are segmented into two general
categories: commercial and consumer. Consumer applications include potable water
supplies, pools, spas and fountains. Commercial applications include pools, spas
and fountains, as well as cooling towers, health care facilities, agriculture,
marine mammal habitats and industrial use. In addition, the Company sells Axenohl
through license agreements as a household and commercial hard surface disinfectant,
for veterinary medicine applications and for dental applications.

The Company's strategy is to license its products for specific applications
in geographic areas. To date, the Company has licensed product applications in
municipal drinking water and wastewater applications, point of entry/point of use
drinking water applications, dental water lines, food processing and health care
applications.

Competitors

The markets in which the Company competes are highly competitive and most
are fragmented, with numerous regional and local participants. The Company,
however, believes it has a competitive advantage because few, if any, of its
competitors have the ionization technology found in RMS and Axenohl. Furthermore,
the few companies that employ ionization are small, local operations, with sales
of less than two million dollars annually. No other ionization company has the
ability to disinfect municipal drinking water or wastewater. Moreover, national
and international patents protect the Company's processes. Management does not
consider any of the ionization technology company competitors significant, when
compared to competition from the chemical industry and from other disinfection
technologies.

The Company has focused on specific market applications for its products.
For example, the RMS is targeted for industrial and large-scale water disinfection
projects, including hospitals, municipal wastewater treatment facilities and large
hotels. IDS represents the "mid-range" applications, typically light-industrial/
commercial and residential. Specific IDS applications may include small hotels,
schools and restaurants. The Company's SAS product line is a circulation system
designed for pools and spas, as well as agricultural sprayers, irrigation and
greenhouses. These three distinct ionization product lines can meet the needs of
all types of consumers in the water purification marketplace.

The Company's final product line is Axenohl, a stabilized, ionic silver
concentrate, which can be used as an additive for an array of disinfection products,
including hard-surface disinfectant, water treatment and veterinary applications.

The Company has applied for and expects to receive Environmental Protection Agency
("EPA") certification for Axenohl. The Company has taken all action it believes
necessary to receive certification. Once it receives EPA certification, the Company
will submit Axenohl to the U.S. Department of Agriculture ("USDA") and the Food
and Drug Administration ("FDA") for certification for human topical and human internal
use. The Company believes that if it receives FDA certification, Axenohl's market
may enlarge to include such diverse products as soaps, shampoos, acne medicine,
athlete's foot treatment and mouthwash.

The Company believes that its products - all environmentally friendly
alternatives to conventional chemical water treatment technologies - are well-positioned
to benefit from a general decline in the use of chlorine. The Company's philosophy
and its products are tied to the general message of reducing or eliminating toxic
chemicals and improving the environment. This philosophy distinguishes the Company
from more conventional chemical water treatment companies. The Company believes
that while other environmentally friendly alternatives including ultra-violet,
ozone and reverse osmosis, will also gain market share, ionization is well suited
for use in conjunction with these alternative technologies.

The Company recognizes that some of its competitors, such as United States
Filter Corporation and Culligan, are multi-line companies with substantially greater
resources than the Company. The Company believes, however, that its focus on specific
market applications and its environmentally friendly philosophy will allow it to
compete in both domestic and global markets.

License Agreements

The Company has a Royalty Agreement with Mr. Andrew Arata for the Axenohl
product line. Mr. Arata is the inventor of Axenohl.Under the terms of the agreement,
he is paid 5% of gross revenues received by the Company from the sale of Axenohl
in perpetuity.

Wallace & Tiernan, Ltd. (UK), a subsidiary of United States Filter
Corporation, entered into an agreement in perpetuity with EHPCI, Ltd. for non-
exclusive worldwide manufacturing and distribution rights for the RMS system.
Since the Company held the exclusive North American license from EHPCI, Ltd. it
became a party to the agreement between EHPCI, Ltd. and Wallace & Tiernan, Ltd.
Under the terms of the worldwide agreement, the Company receives a royalty of
12 1/2% of the gross selling price for all units sold in North America, and has
the option to purchase any RMS systems produced under private label by Wallace &
Tiernan, Ltd. for cost plus 28%. EHPCI, Ltd. recently assigned its RMS technology
rights to an affiliated company, GWR, Ltd. As noted in the discussion of the
Company's RMS product line above, in the fourth quarter of 2000, the Company
acquired ownership and control of EHPCI, Ltd.. To date, however, the Company has
earned no revenue under the Wallace & Tiernan, Ltd. agreement.

The Company entered a five-year manufacturing and distribution agreement
with ETI-H2O on November 30, 1998 to produce and sell the Axenohl product line
exclusively in the country of Costa Rica and in the southeastern United States,
including Florida, Georgia, Alabama, Mississippi, Louisiana, South Carolina,
North Carolina, Virginia, Tennessee and Kentucky. The agreement expires in 2003.
To date, the Company has earned no revenue under this agreement.

ETI-H2O also signed a two-year Standard Manufacturing Agreement on September
17, 1999 for manufacture and marketing of the Axenohl product for New Zealand,
Australia, Thailand, Philippines, Singapore and Malaysia. Under the terms of the
agreement, the Company receives an escalating royalty on Axenohl sales. The
agreement expires in September 2001. To date, the Company has earned no revenue
under this agreement.

On November 24, 1999, the Company executed a license agreement with IMS
for distribution and sale of Axenohl for dental waterline applications, certain
healthcare markets, food processing and point of use/ point-of-entry applications
in specified geographical territories. Under the agreement, the Company receives
fifty percent (50%) of any up-front license fees received by IMS in the course of
sub-licensing the product to third party distributors and a 15% royalty based on
the manufactured cost of Axenohl sold by IMS. The agreement expires in December
2002. To date, the Company has earned no revenue under this agreement. To the extent
that amounts are paid to the Company under this Agreement, the Company is obliged
to pay 2.5% of such amounts to Dr. Charles Lewis as compensation for introducing
the Company and IMS.

Intellectual Property

Patents. All of the products developed by the Company are protected by
U.S. and PCT country patents pending. As a result, the Company has very few direct
competitors using the same technology. The Company has competitors who use different,
more conventional technologies, including chlorine, ultraviolet, ozone, chlorine
dioxide, reverse osmosis, copper and silver.

The Company has received United States Letters Patent for Axenohl. The
patent was issued in March 2001. The Company has also sought patent protection
for Axenohl under international treaty. The Company owns the property rights to
Axenohl under an assignment from Axenohl's inventor, Andrew Arata.

Trade Secrets. Three of the four product lines carried by the Company
use trade secrets involving ionization: RMS, IDS and Axenohl. Each of these products
uses the stabilization of silver ions, which normally have a shelf life of only
three to four hours. By utilizing the Company's discoveries, however, silver ions
can be stabilized for periods in excess of six months.

These trade secrets are significant because although there are several
alternatives to chlorine in water disinfection applications, the Company's process
is the only solution with a long-term disinfecting residual. The loss of these
trade secrets could have a material, adverse effect on the Company's business.

Research & Development

The Company's current research and development focuses on expanding the
applications for the Company's existing product line and licensing additional
corporate partners. Current research and development projects include RMS applications
for Legionella control in hospital settings. Axenohl is being tested for certain
agricultural and horticultural applications, municipal drinking water systems and
veterinary medicine. The Company has also applied for and expects to receive EPA
certification of Axenohl. ETI-H2O submitted the necessary information to the EPA
on behalf of NVID, and was paid by NVID for their services. The Company and ETI-H2O
have taken all action it believes necessary to receive certification. Assuming the
Company receives EPA certification, it intends to test Axenohl for hard surface
disinfectants and for use in direct food contact (for instance, poultry and seafood)
and, as noted previously, the Company plans to apply for FDA certification of Axenohl.

If the Company receives EPA approval for Axenohl, it will apply for FDA
certification for Axenohl's use as a human topical disinfectant and for use
internally by humans. The Company estimates the cost of obtaining FDA certification
for Axenohl's use as a human topical disinfectant at approximately $150,000 based
on the Company's prior testing experience. Based on similar information, the Company
believes it would cost between $650,000 and $750,000 to obtain FDA approval for
Axenohl's use internally by humans. The time for receiving FDA certification is
estimated to be 8-12 months for human topical uses and 3-4 years for human internal
applications. Assuming the Company has obtained EPA certification of Axenohl and
has reached profitability during the third quarter of 2001, it would begin the
FDA certification process by the end of 2001. The Company believes that if it receives
FDA certification of Axenohl, the market for Axenohl has the potential to increase
significantly due to Axenohl's use in products for human consumption, including
shampoo, acne medicine and mouthwash.

Government Regulation

The RMS technology has received the necessary government approvals for use
in drinking water disinfection in Mexico. Axenohl formulations have been submitted
to the EPA for approval. The Company has taken all action it believes necessary to
receive certification. Upon EPA approval, Axenohl will be submitted to the USDA and
the FDA for their approval. The Company is presently working with the USDA in related

laboratory and field studies. For example, the USDA and the Company have entered
a Trust Fund Cooperative Agreement for a field study at the USDA facility in Athens,
Georgia. The study is funded and commenced July 1, 2000. The subject of the study
is to determine the efficacy of Axenohl in replacing toxic disinfectants used in
poultry production. This study is ongoing and is expected to be completed by July
1, 2001. Until completion, the study's results will not be available to the general
public.

Additionally, the Company submitted samples of Axenohl
for testing against the Vancomycin Resistant Enterococcus virus. The Company
submitted the report from an independent laboratory detailing Axenohl's
efficacy against the virus to the FDA. Both studies concluded the Axenohl formulations were
99.9999% effective against the subject virus strains at low levels.

Environmental Issues

The Company's product lines produce pesticides to treat a variety of bacteria,
viruses, fungi and pathogenic organisms. The primary biocide used in ionization is
ionic silver with trace amounts of other metals. The Company has never received a
notice or demand from any environmental authority regarding its products. In
addition, the Company has licensed the manufacture of its products to other companies,
and therefore does not require any environmental permits itself.

Prior to 1993, the EPA set the amount of silver recommended for drinking
water at 100 parts per billion. In 1993, the EPA dropped silver from the EPA's
primary water standards, though it was retained at 100 parts per billion for the
secondary water standards that are used as guidelines by states for setting their
own standards. Management expects that the EPA will drop silver eventually from
its secondary standards.

The EPA is reducing the amount of THMs allowed in drinking water from 100
parts per million to 80 parts per million. Trihalomethanes are known carcinogens
formed when chlorine is combined with organic matter found in nature. The anticipated
effect of the reduction in THMs is a greater emphasis on technologies that reduce
or eliminate the use of chlorine. The Company expects to gain market share in all
of its product lines as a result of a reduction in THM levels allowed in drinking water.

Business Plan

The next phase of the Company's development is establishing a significant
revenue stream and achieving profitability. The Company seeks to increase its gross
sales to $8,000,000 by 2003. To do so, it must position its ionization technologies
at the forefront of the water disinfection industry. The keys to the Company's
success include improvements in:

o Marketing and Sales.

o Manufacturing.

o Product Development, Testing and Licensing.

o Administration.

Estimated Expenditures

The Company estimates expenditures in the four key areas noted above to
total $2,720,800 through 2003. The estimated expense for Marketing and Sales is
$55,800 which includes operation and maintenance of the Company's website. The
Company does not anticipate any significant expense for Manufacturing, since it
does not currently manufacture its own products. As discussed in more detail below,
the Company is seeking to acquire Superior Aqua Enterprises, the current manufacturer
of the Company's SAS product line. If that transaction closes, the Company estimates
a possible cash expense of approximately $15,000. Product Development, Testing, and
Licensing is the Company's most significant category of anticipated expense. Based
on current estimates, the Company plans to spend over $973,000 in product development,
testing, and licensing over the next three years, with 85% of the expenses occurring
after January 2002. Finally, the Company estimates spending $1,692,000 over the next
three years in Administration expenses, due to anticipated increases in the number
of Company employees.

Marketing and Sales. The Company's marketing plan calls for the creation
of "flagship" accounts for industry-specific field tests to showcase the economic
feasibility and efficacy of the Company's products in various applications. The
Company has established flagship accounts with:

o Hospital General Mexico, Mexico City, Mexico (Water disinfection).

o Methodist Hospital, Indianapolis, Indiana (Legionella control).

o Dine S. A. de C.V., Mexico City, Mexico (Municipal drinking water).

o Rotoplas, S.A. de C.V. Mexico City, Mexico (Residential drinking water).

o La Laqunilla, San Francisco, Villa Guerrero, Mexico (Agriculture).

o Charing Cross Hospital, London, UK (Legionella control).

o BBC Headquarters Building, London, UK (Legionella control, drinking
water).

o Heathrow Airport, London, UK (Legionella control, drinking water).

o Kew Gardens, London, UK (Horticulture).

The Company has already funded these accounts and does not anticipate incurring
any further expenses in connection with these field tests.

After a flagship account has completed testing, the Company anticipates
licensing its products to the former flagship account for an initial license fee
and an ongoing royalty. As the Company emerges from its current stage, it expects
to license entities in a broad spectrum of applications for the Company's products.
Generally, these licenses will be for specific product applications within specific
geographic areas and will contain mandatory performance criteria for the licensee
to maintain the license. The Company's marketing and sales success depends on the
success of its corporate partners.

Currently, the Company has signed licensing agreements with four (4)
corporate partners:

1) Innovative medical Services. On November 24, 1999, the Company entered
a three year license agreement with Innovative Medical Services ("IMS")
for the distribution and sale of Axenohl for specific geographic and
market segments. IMS may market Axenohl in the Point of Use, Point-of-Entry,
Healthcare, Food Processing and Dental Markets in certain described geographic
territories. The license includes an automatic renewal for an additional
three-year term.

2.) ETI-H20, Inc. On November 30, 1998, the Company entered a five-year
Standard Manufacturing Agreement with ETI-H20. Pursuant to the
agreement, ETI-H20 may manufacture and sell Axenohl exclusively in the
Southeastern United States (Florida, Georgia, Alabama, Mississippi,
Louisiana, South Carolina, North Carolina, Virginia, Tennessee and Kentucky)
and Costa Rica. NVID will receive a royalty of 15% of the gross price
for all product sold in these territories after December 5, 2000. NVID
also has the option of buying out ETI-H20's rights under the agreement
at anytime.

4.) Aqua Bio Technologies, S.A. de C.V. A license agreement was executed
March 5, 2000 between the Company and Federico Rodriguez, a principal
and officer of Aqua Bio Technologies, S.A. de C.V. for the exclusive
distribution of Axenohl in Mexico. The March 5, 2000 license agreement
augments a distribution agreement between the Company and Aqua Bio
Technologies S.A. de C.V. dated March 5, 2000 for the distribution and
sale of the Company's RMS, IDS and SAS product lines in Mexico.

The Company plans to expand its marketing and sales operations in the near future
by the addition of the following corporate partners:

Event Expected Completion
Date
Rotoplas S.A. de C.V. (licensing Axenohl for residential July 31, 2001
drinking water for Mexico)

Adams Healthcare, Ltd. (licensing Axenohl for hospital July 1, 2001
disinfection in the United Kingdom)

Vivendi Environmental (licensing RMS for cooling towers and March 31, 2002
Legionella control in hospital settings and large municipal
water systems).

In addition to the potential corporate partners noted above, the Company
is also negotiating for the acquisition of a fifty percent (50%) equity interest
in Watertronics, Ltd. Negotiations are ongoing, and the Company hopes to close the
transaction by the end of June, 2001.

The Company estimates additional marketing and research expenses at $5,000
per year for the next three years ($15,000). The Company also anticipates spending
$5,000 to complete a database system and $25,000 to complete and print promotional
materials, plus an additional $3,600.00 per year to maintain the Company's website.

Manufacturing. The Company does not manufacture its own products. Currently,
the Company's RMS and IDS products are manufactured exclusively by Westlund
Engineering, Inc. of Clearwater, Florida. The Company's SAS product line is
manufactured by Superior Aqua Enterprises, Inc. of Sarasota, Florida. Axenohl is
manufactured for the Company by ETI-H2O of Lake City, Florida.

On December 4, 2000, the Company signed a Letter of Intent to acquire
Superior Aqua Enterprises, Inc., thereby bringing the manufacturer of the SAS
product line under its control. One of the conditions to closing of the transaction
was the ability of the parties to account for the transaction as a "pooling of
interests." The parties determined "pooling of interest" treatment was not available.
Consequently, the parties are continuing to negotiate the terms of the transaction,
particularly the payment terms, which may involve the payment by the Company of
cash and equity consideration.

Product Development, Testing and Licensing. To maximize the Company's
sales, it has focused its research and development on identifying additional market
applications for its existing products. Current research and development includes
product testing for a number of different industry applications, including municipal
drinking water, agriculture, wastewater treatment and Axenohl's use for veterinary,
human topical and internal consumption. The Company is pursuing necessary government
and regulatory approval for key products. The material goals that the Company is
pursuing in this area, together with their expected completion dates, are set forth
in the following table:

Event Expected Completion Date

1. Testing Axenohl for use in citrus canker and fungus January 15, 2001
control, San Jose, Costa Rica. Funded

2. Testing Axenohl for drinking water use, San Jose, Costa January 15, 2001
Rica. Funded

3. Testing IDS for municipal wastewater treatment, April 15, 2001
Cincinnati, Ohio. Funded by PDF Tech, Inc.

4. EPA Certification for Axenohl, Washington, D.C. July 31, 2001
Funded

5. Testing Axenohl on agave plant for the tequila industry, April 30, 2001
Guadalajara, Mexico. Estimated Cost
$8,000
6. Testing Axenohl as a fruit wash and fungus control, San April 15, 2001
Jose, Costa Rica. Funded

7. Testing Axenohl for poultry applications by the USDA, June 30, 2001
Athens, GA. Funded

8. USDA Certification for Axenohl, Washington, D.C. December 31, 2001
Estimated Cost $25,000

9. Testing RMS and Axenohl for municipal drinking water in August 23, 2001
Mexico City, Mexico. Estimated Cost $28,000

10. Testing RMS for bio-film reduction in Mexico City's June 15, 2001
Hospital General. Estimated Cost $2,000

11. FDA Certification for Axenohl's use as a human topical September 15, 2002
disinfectant. Estimated Cost $150,000

12. FDA Certification for Axenohl's use internally by October 15, 2004
humans. Estimated Cost $750,000

13. Testing IDS for well water treatment, Celaya, Mexico. June 1, 2001
Estimated Cost
$10,000

14. Testing Axenohl for human use applications, Mexico June 1, 2001
City, Mexico. Estimated cost unknown at
present. Company will
receive estimate by May 31,
2001.

#1 Testing Axenohl for use in citrus canker and fungus control, San Jose, Costa Rica.
This test was funded by ETI-H20 and the test concluded on January 15, 2001. The test
was intended to prove the efficacy of Axenohl(TM)in controlling citrus canker. Although
the test has concluded, the findings have not yet been disclosed. ETI-H20 has indicated
the results were positive; we should have a full report of the test by the end of April 2001.

#2 Testing Axenhol for drinking water use, San Jose, Costa Rica. This water
study has been completed. The study proved that Axenohl(TM)can be used as a "stand-alone"
disinfectant in treating municipal water systems. This study was funded by ETI-H20.

#3 Testing IDS for municipal wastewater treatment, Cincinnati, Ohio. This is
an on-going test by a potential distributor under the auspices of the EPA. RDF Tech, Inc.
is funding the test. Preliminary results have proved successful. Our only expense in
this test was the cost of providing an IDS unit. This test should be completed timely.

#4 EPA Certification for Axenohl, Washington, D.C. This testing has been funded
and poses no additional expense to the Company. We have been in contact with the EPA
regarding the status of our application and are awaiting agency action.

#5 Testing Axenohl on agave plant for the tequila industry, Guadalajara, Mexico.
The agave plant is dormant during the winter and actual field studies have been suspended
until March 2001. We completed lab tests conducted by the agave growers association and it
appears Axenohl can kill the fungus and bacteria which effect the plant. During this
dormant period, testing will move into a certification laboratory setting, which is
required in order to sell the product in Mexico. We expect to begin and conclude this
portion of the testing in the second quarter of 2001. The overall field study will
begin thereafter and will continue for two additional months. The Company has incurred
no expense to date on these tests, with the exception of supplying the Axenohl(TM)
concentrate. The up-coming certification expense will be paid by the Company . The
cost is estimated at $8,000. The Mexican tequila industry has sales of $550 million
dollar per year, and the Company believes Axenohl will provide the results the industry
needs to effectively control fungus and bacteria. The Company expects to complete the
tests on schedule.

#6 Testing Axenohl as a fruit wash and fungus control, San Jose, Costa Rica.
This test is funded by ETI-H20. ETI-H20 is conducting the tests in an effort to sell
Axenohl to fruit growers in Costa Rica. The Company has not seen any results from this
test and is not aware of any reason why the test will not be completed on time.

#7 Testing Axenohl for poultry applications by the USDA, Athens, Georgia.
The Axenohl(TM)supplied originally by the Company to the USDA proved efficacious,
but the second batch less so. The Company suspected the second batch of Axenohl(TM)was

contaminated and the Axenohl was turned over to an independent lab for testing.
Testing confirmed the contamination. Following receipt of a new Axenohl delivery,
testing began anew. Interim reports reflect a 5-log reduction of bacteria using
Axenohl. This 5-log reduction is greater than any product currently on the market.
This test will conclude during June of 2001. The Company hopes this testing and the
results will lead to fast track status for Axenohl for USDA approval. The tests
should conclude on time.

#8 USDA Certification for Axenohl, Washington, D.C. The Company has not
applied for USDA certification because EPA certification is required prior to submittal.
The Company estimates submitting an application for USDA certification within one month
after receiving EPA certification. Since the USDA is familiar with Axenohl(TM)from its
Axenohl poultry testing, the Company is hopeful the USDA certification process can be
completed in a timely fashion, and before the end of 2001.

The Company underestimated the time required to obtain an EPA response to its
Axenohl application. This has set back the estimated completion date for USDA
certification by six to eight months.

#9 Testing RMS and Axenohl for municipal drinking water, Mexico City, Mexico.
Mexico City receives all of its municipal water supply from sea level. The water is
pumped over 6,800 feet to Mexico City. Once the water reaches the existing water
distribution system, seventy percent (70%) is lost to leakage. Due to the 1984
earthquake and settling of the city (30' in 100 years), Mexico City suffers from a
water distribution system wrought with leaks. Repairing the distribution system is
not feasible until the settling has been stabilized, which involves replenishment of
the aquifer.

The Company made a presentation to Mexican government officials in 1997,
introducing ionic silver technology. The Company proposed:

1. Using ionic silver to purify rainwater and pump the treated water into
the aquifer.
2. Complete repair of the distribution system could span 25 years, so the
Company proposed interim protection with IDS, RMS, or Axenohl(TM)in:
a. Schools
b. Hospitals
c. Government Buildings
d. Airports
e. All public facilities

Mexico's newly elected President, Vincente Fox is considered pro environment
and referred to water as "a matter of national security" in his inauguration speech.
The Company has been requested to make another presentation to the planning commission
of Mexico City, the Director General of the Airports, Salute de Ambiental, and the
Commission National de Agua.

Any contract will require testing to prove the efficacy of the Company's process.
Fortunately, the Company believes, based on past experience, that efficacy tests can be
conducted on a small scale and the equipment cost, shipping, handling, installation, and
independent laboratory analysis, can be provided for approximately $28,000.

The Company's Mexican affiliate, Aqua Bio Technologies, S.A. de C.V. met with
the planning department on February 9, 2001 to set a presentation agenda. The Mexican
government agreed to supply a project director and assistants for preliminary testing
at no cost to the Company.

The Company does not foresee any problems with future presentations or testing,
but cautions that in dealing with government entities, plans are subject to change on
very short notice. At best, the Company's plans and dates are merely estimates.

#10 Testing RMS for bio-film reduction in Mexico City's Hospital General, Mexico City, Mexico.
Mexico City's Hospital General, already has one of the Company's RMS units installed on
its main cistern. The unit had been operating for two years when it was hit by lightning.
The unit was returned to the US for repair and was therefore out of commission for 45 days.
While the unit was being repaired, the hospital used water supplied by the municipal authority.
During that time, the hospital noted a sharp increase in skin disorders, rashes, and fungal
infections, as well as higher bacteria counts in drinking water. The hospital attributed the
increase to lack of ionic silver in the water supply. Based on the foregoing, the hospital
decided to conduct tests beginning March 12, 2001 on bacteria counts and how water treated
with ionic silver affected patient's skin disorders. All test results and the study will be
shared with the Company. The tests are estimated to conclude on June 15, 2001. The Company's
only estimated expense is a project coordinator (approximately $2,000). The Company has no
reason to suspect this test will not be completed on schedule.

#11 FDA Certification for Axenohl's use as a human topical disinfectant, Washington, D.C.
The Company is not eligible to apply for FDA topical certification for Axenohl until
it receives EPA certification for Axenohl. Therefore, any dates noted represent only
estimates. The Company would like to start testing within three months after it receives
EPA certification. Because this certification has the potential to create an entirely new
line of significant products, the Company's Board of Directors would consider funding the
project.

#12 FDA Certification for Axenohl's use internally by humans, Washington, D.C.
The expense and time requirements necessary to acquire FDA human use internal certification
are significant. The Company is not eligible to even apply for FDA certification for
Axenohl's use internally by humans until it receives EPA approval and completes a series
of independent tests. NVID, however, was contacted by the FDA Human Internal Use section
and asked to participate in a test designed to test the efficacy of Axenohl(TM)against

Vancomycin-Resistant Enterococci (VRE). Axenohl proved 99.999 % effective against VRE and
the Company was told that the results of this test would give the Company "fast track"
status if the Company submits for FDA certification. ETI-H2O has assisted NVID at
both the EPA and FDA levels for all testing and correspondence.

#13 Testing IDS for well water treatment, Celaya, Mexico. The testing conducted
on cooling towers in Celaya, Mexico came to the attention of the of the city's water
department's director. The city of Celaya presently has 120 wells; 60 wells are urban
and 60 are rural. The city is exploring disinfection technologies (other than chlorine)
to treat the city's water supply.

After the Company held numerous meeting with city officials, it was decided to
demonstrate ionic silver technology by conducting a test on one urban and one rural well.
The same machinery utilized in the cooling tower test was refurbished and augmented by an
additional unit which cost the Company $3,000. The test commenced on January 15, 2001 with
one unit installed on a urban well. The second unit was shipped from the U.S. on January
30, 2001 and is now operating. The testing will continue until April 30, 2001. If the
testing is successful, the city will purchase the two test units and begin negotiating with
the Company for treating all the city's wells.

We estimate the testing will cost the Company $10,000, including the equipment,
laboratory, shipping, and installation. We do not foresee any potential problems that
would delay the tests' completion.

#14 Testing Axenohl for human topical use applications, Mexico City, Mexico.
The Company is eligible to submit an application to Salutede Ambiental for Axenohl's
certification for human topical use in Mexico. The Company has conducted many informal
tests utilizing Axenohl(TM)in human use applications ranging from additives in shampoos,
soaps and cosmetics to acme medicine. The Company's management, based on the results of
these informal tests, is convinced that there is a large potential market for human
topical use in Mexico. Additionally, many Latin American countries recognize Mexican
certification. The Company's management met with Mexico's largest cosmetic companies
in February 2001 to discuss utilizing AxenohlTM as an additive in products and is
pursing negotiation with Avon Mexico for testing protocols.

Estimated Testing Costs The total estimated cost for the testing reflected
above is $973,000 over the next three years, with 85% of the testing costs occurring
after January 2002. Many of the tests have already been funded. The Company plans to
fund certain remaining tests from the sales proceeds of restricted stock. These tests
are scheduled to begin prior to the Company's anticipated profitability in the third
quarter of 2001, and total $48,000, including testing for the agave plant, municipal
drinking water in Mexico City and the Celaya, Mexico well water tests. The Company
hopes to fund the remaining tests after it reaches profitability in late 2001.

Administration. The Company's administration is handled currently by its
executive officers. The Company plans to expand its office and administrative staff
in 2001 to accommodate and better serve both stockholders and the Company's
distributors and corporate partners. Currently, the Company plans to hire five
(5) new employees in 2001. The Company has tentative plans to hire additional
employees as needed. The Company estimates the cost of the five additional new
employees in 2001 at $500,000.00. The Company is developing and will complete by
the first quarter of 2001 new marketing materials and the Company's website.

Risk Factors

The Company likely will require additional financing. The Company has very
limited funds, and the funds may not be adequate to take advantage of all available
business opportunities. The ultimate success of the Company may depend upon its
ability to raise additional capital. The Company has not ascertained the availability,
source, or terms that might govern the acquisition of additional capital and will
not do so until it determines a need for additional financing. If additional capital
is needed, there is no assurance that funds will be available from any source or,
if available, that they can be obtained on terms acceptable to the Company. If
additional financing is not available, the Company's operations will be limited to
those that can be financed with its modest capital.

The Company's stock is regulated. The Company's securities are subject to a
Commission rule that imposes special sales practice requirements upon broker-dealers
who sell such securities to persons other than established customers or accredited
investors. For purposes of the rule, the phrase "accredited investors" means, in
general terms, institutions with assets in excess of $5,000,000, or individuals
having a net worth in excess of $1,000,000 or having an annual income that exceeds
$200,000 (or that, when combined with a spouse's income, exceeds $300,000). For
transactions covered by the rule, the broker-dealer must make a special suitability
determination for the purchaser and receive the purchaser's written agreement to
the transaction prior to the sale. Consequently, the rule may affect broker-dealers'
ability to sell the Company's securities and also may affect the ability of
purchasers to sell their securities in any market that might develop for them.

In addition, the Commission has adopted a number of rules to regulate
"penny stocks." Such rules include Rules 3a51-1, 15g-1, 15g-2, 15g-3, 15g-4, 15g-5,
15g-6, 15g-7, and 15g-9 under the Securities Exchange Act of 1934, as amended. Because
the securities of the Company may constitute "penny stocks" within the meaning of
the rules, the rules would apply to the Company and to its securities. The rules may
further affect the ability of shareholders to sell the Company's securities in any
market that might develop for them.

Shareholders should be aware that, according to the Commission, the market
for penny stocks has suffered in recent years from patterns of fraud and abuse. Such
patterns include (i) control of the market for the security by one or a few broker-dealers
that are often related to the promoter or issuer; (ii) manipulation of prices through
prearranged matching of purchases and sales and false and misleading press releases;
(iii) "boiler room" practices involving high-pressure sales tactics and unrealistic
price projections by inexperienced sales persons; (iv) excessive and undisclosed bid-ask
differentials and markups by selling broker-dealers; and (v) the wholesale dumping of
the same securities by promoters and broker-dealers after prices have been manipulated
to a desired level, along with the resulting inevitable collapse of those prices and
with consequent investor losses. The Company's management is aware of the abuses that
have occurred historically in the penny stock market. Although the Company does not
expect to be in a position to dictate the behavior of the market or of broker-dealers
who participate in the market, management will strive within the confines of practical
limitations to prevent the described patterns from being established with respect to the
Company's securities.

The Company has no operating history. The Company has been engaged in its
current business only since 1994. During the last five years the Company has focused
on developing and refining its products and expanding the applications for those products.
Due to the lack of an operating history, specifically the absence of substantial sales
volume, the Company must be regarded as a new or start-up venture with all of the
unforeseen costs, expenses, problems, and difficulties to which such ventures are subject.

The Company is not diversified. Because of the Company's limited financial
resources, it is unlikely that the Company will be able to diversify its acquisitions
or operations. That means the Company's operations and products will only focus on the
water purification and disinfection market. The Company's inability to diversify its
activities into more than water purification and disinfection will subject the Company
to economic fluctuations and regulatory changes within its particular business or industry
and therefore increase the risks associated with the Company's operations.

The Company is obligated to indemnify its officers and directors. Delaware
law and the Company's Certificate of Incorporation provide for the indemnification
of the Company's directors, officers, employees, and agents, under certain circumstances
against attorney fees and other expenses incurred by them in any litigation to which
they become a party arising from their association with or activities on behalf of the
Company. The Company will also bear the expenses of such litigation for any of its
directors, officers, employees, or agents, upon such person's promise to repay the
Company, if it is ultimately determined that any such person was not entitled to
indemnification. This indemnification policy could result in substantial expenditures
by the Company that it will be unable to recoup.

The Company's directors have limited liability under Delaware law. Delaware
law and the Company's Certificate of Incorporation exclude the personal liability of
directors to a company and its stockholders for monetary damages or for breach of
fiduciary duty except in certain specified circumstances. Accordingly, the Company
will have a much more limited right of action against its directors than otherwise
would be the case. This provision does not affect the liability of any director under
federal or applicable state securities laws.

The Company does not anticipate paying dividends in the foreseeable future.
The Company has not paid dividends on its common stock and does not anticipate paying
such dividends in the foreseeable future.

The Company's limited operating history makes forecasting difficult. Although
the Company was founded in August 1984, it did not enter the water purification and
disinfection business until 1994. From 1994 until 1997 the Company had minimal sales.
When current management took control of the Company in 1997, it had just been named as
a defendant in a civil action brought by the SEC stemming from the actions of two
Company officers arrested for misappropriation of stockholder funds and fraud. After
settling the SEC litigation and following the resignation of culpable former management,
the Company's operations focused on the development of Axenohl and the RMS, SAS
and IDS water purification systems. To date, almost all of the Company's efforts have
focused on product development and applications. The Company has very limited,
meaningful historical financial data on which to base projected revenues and planned
operating expenses and upon which investors may evaluate the Company and its prospects.
In addition, the Company's operating expenses are largely based on anticipated revenue
trends. You should consider the risks and difficulties frequently encountered by companies
like NVID in a new and rapidly evolving market. The Company's ability to sell products,
and the level of success, if any, it achieves, depends, among other things, on the level
of demand for water purification and disinfection products and the success of the Company's
licensed corporate partners and distributors. If the Company does not achieve the Company's
expected revenue, its operating results will be below expectations and the expectations
of its investors, which could cause the price of the Company's common stock to decline.

Failure to increase revenue would prevent the Company from reaching profitability.
The Company has a history of losses and hopes to achieve profitability for the first
time in 2001. There is no assurance that the Company's revenue will grow or that it will
generate sufficient revenue to become profitable. The Company expects to continue to
incur significant and increasing sales and marketing, product development, administrative
and other expenses. Although the Company's revenue has grown in recent quarters, there is
no certainty that revenue growth will continue or increase in the future or that the
Company will realize sufficient revenue to sustain profitability on an annual or quarterly
basis.

The Company is entirely dependent on its ionization line of water purification
and disinfection products, and future revenue depends on their commercial success. The
Company's future growth depends on the commercial success of its ionization products,
including Axenohl. To date, the IDS, SAS and RMS product lines have been sold on a
limited basis, primarily in connection with testing and research. Axenohl has also
been sold in limited quantities and for testing purposes. The Company intends to
develop enhancements and to refine existing products, and to expand the applications
for existing products in the future. The Company cannot assure that it will successfully
complete the development or introduction of new products, or successfully identify
alternative applications for existing products. Failure of current or planned products
to operate as expected could delay or prevent their adoption. If target customers
do not purchase and successfully deploy current and planned products, the Company's
revenue will not grow significantly.

The Company will not be successful if its customer base does not grow. The
Company's future success depends on attracting additional customers. The growth of
the Company's customer base could be adversely affected by:

o customer unwillingness to install or utilize the Company's products;

o customer inability to devote capital to acquire the Company's products;

o any delays or difficulties incurred in completing the development,
licensing and introduction of planned products or product enhancements;

o new product introductions by competitors;

o any failure of the Company's products to perform as expected; or

o any difficulty incurred in meeting customers' delivery requirements or
servicing expectations.

o changes to laws, regulations or licensing requirements applicable to the
Company's products.

If the Company does not respond rapidly to technological changes, its products
could become obsolete. The market for water purification and disinfection products is
likely to continue to be characterized by change and development, new products and
technologies, and changes in customer requirements. The Company may be unable to
respond quickly or effectively to these developments. The Company may experience
design, manufacturing, marketing and other difficulties that could delay or prevent
development, introduction or marketing of products and product enhancements. The
introduction of new products by competitors, market acceptance of products based
on new or alternative technologies or the emergence of new industry standards or
technologies could render existing or future products obsolete.

In developing products, the Company has made, and will continue to make,
assumptions about the standards that may be adopted by customers and competitors.
If the standards adopted are different from those the Company has chosen to support,
market acceptance of products may be significantly reduced or delayed and the Company's
business will be seriously harmed. In addition, the introduction of products
incorporating new technologies and the emergence of new industry standards could
render the Company's existing products obsolete.

The Company may not become profitable unless Corporate Partners and distributors
successfully expand sales, service support operations. The Company's product sales
depend upon the successful efforts of its corporate partners and distributors. The
Company has existing license agreements with over half a dozen corporate partners
and distributors. Current licensing arrangements provide a distribution network for
the Company's products encompassing both domestic and international markets, including
North America, the United Kingdom, Mexico, Central and South America and the Pacific
Basin. The Company is building a sales network and plans to license additional partners
as needed. If distributors and corporate partners are unable to expand their sales
operations or service effectively the Company's existing customers, the Company may
not be able to increase market awareness or product sales, which may prevent the
Company from reaching and maintaining profitability.

The Company depends upon contract manufacturers, and any disruption in these
relationships may cause the Company to fail to meet the demands of its customers and
damage customer relationships. The Company does not manufacture its own products.
It relies on several contract manufacturers to manufacture products in accordance with
the Company's specifications, and to fill orders on a timely basis. Currently, the
Company's RMS and IDS products are manufactured exclusively by Westlund Engineering,
Inc. of Clearwater, Florida. The Company's SAS product line is manufactured by Superior
Aqua Enterprises, Inc. of Sarasota, Florida. Axenohl is manufactured for the Company by
ETI-H2O, Inc. of Lake City, Florida.

The Company may be unable to manage its relationships with its manufacturers
effectively, and these manufacturers may not meet future requirements for timely delivery.
Each contract manufacturer builds products for other companies, and cannot assure the
Company that they will always have sufficient quantities of inventory available to fill
orders placed by the Company's customers, or that they will allocate internal resources
to fill these orders on a timely basis. Qualifying new contract manufacturers and
commencing volume production is expensive and time consuming and could result in a
significant interruption in the supply of products. If required to change contract
manufacturers, the Company may lose revenue and damage its customer relationships.

The Company's failure to continually improve internal controls and systems
and hire needed personnel, could impair future growth. The Company's operations
have expanded considerably since 1997, and the Company continues to increase the
scope of its operations. Growth has placed, and anticipated growth will continue
to place, a significant strain on management systems and resources. The Company's
ability to offer products and implement a business plan successfully in a rapidly
evolving market requires an effective planning and management process. The Company
expects that it will need to continue to improve its financial, managerial and
manufacturing controls and reporting systems, and will need to continue to expand,
train and manage relationships with corporate partners and distributors worldwide.
The Company may not be able to implement adequate control systems in an efficient
and timely manner. Any failure to attract, assimilate or retain qualified personnel
to fulfill current or future needs could impair The Company's growth.

The Company depends on key personnel to manage its business effectively and
if unable to retain key employees, ability to compete could be harmed. Future success
depends upon the continued services of the Company's executive officers and other key,
sales, marketing and support personnel, who have critical industry experience and
relationships that are crucial to implement the business plan successfully. None
of the officers or key employees is bound by an employment agreement for any specific
term. The Company does not have "key person" life insurance policies covering any
of its employees. The loss of the services of any key employee could delay the
development and introduction of, and negatively impact the Company's ability to
sell, its products.

The Company's ability to compete successfully could be jeopardized if it
is unable to protect its intellectual property rights from third-party challenges.
The Company relies or expects to rely on a combination of patent, copyright, trademark
and trade secret laws and restrictions on disclosure to protect its intellectual
property rights. The Company also enters into confidentiality or license agreements
with employees, consultants and corporate partners, and controls access to and
distribution of documentation, product specifications and other proprietary information.
Despite efforts to protect proprietary rights, however, unauthorized parties may
attempt to copy or otherwise obtain and use the Company's products or technology.
Monitoring unauthorized use of products is difficult and the Company cannot be
certain that the steps it has taken will prevent unauthorized use of technology,
particularly in foreign countries, where the laws may not protect proprietary rights
as fully as in the United States. If competitors are able to use the Company's technology,
its ability to compete effectively could be harmed.

We are uncertain whether we will be able to realize the value of our intangible
assets. A significant portion of the Company's assets consists of intellectual property
and other intangible assets. In the event the Company is unable to implement its business
plan successfully, the Company cannot assure that it will be able to realize the amounts
listed on its balance sheet, or any amount, for such assets. Any successful challenge
to the Company's intangible assets, or any inability to realize the value of those assets
may have a material, adverse effect on the Company's financial position, results of operations
and prospects.

If necessary licenses of third-party technology are not available or are
very expensive, the Company's products could become obsolete. From time to time
the Company may be required to license technology from third-parties to develop new
products or product enhancements. The Company cannot assure that third-party licenses
will be available on commercially reasonable terms, if at all. The inability to obtain
a third-party license required to develop new products and product enhancements,
could require the Company to obtain substitute technology of lower quality or performance
standards or at greater cost, either of which could seriously harm the Company's
competitiveness.

The Company could become involved in litigation regarding intellectual
property rights, which could seriously harm its business and require it to incur
significant costs. In recent years, there has been significant litigation in the
United States involving patents and other intellectual property rights. Although
the Company has not been involved in any intellectual property litigation, it may
be a party to litigation in the future to protect its intellectual property or as
a result of an allegation that it infringes others' intellectual property. Any
parties asserting that the Company's products infringe upon their proprietary
rights would force the Company to defend itself and possibly its customers or
manufacturers against the alleged infringement. These claims and any resulting
lawsuit, if successful, could subject the Company to significant liability for
damages and invalidation of proprietary rights. These lawsuits, regardless of
their success, would likely be time-consuming and expensive to resolve and would
divert management time and attention. Any potential intellectual property litigation
also could force the Company to do one or more of the following:

o stop selling, incorporating or using products that use the challenged
intellectual property;

o obtain from the owner of the infringed intellectual property right a
license to sell or use the relevant technology, which license may not be
available on reasonable terms, or at all; or

o redesign those products that use such technology.

If forced to take any of the foregoing actions, the Company's business may be
seriously harmed.

The Company may face risks associated with its international expansion
that could impair its ability to grow abroad. The Company intends to continue
to expand its sales into international markets. This expansion will require significant
management attention and financial resources to develop successfully international
distribution, sales and support channels and to support customers in international
markets. The Company may not be able to develop international market demand for
its products.

The Company has limited experience in marketing, distributing and supporting
its products internationally and to do so successfully, it expects assistance and
support from its licensed corporate partners. Specifically, the Company will look
to local partners and distributors for guidance in developing versions of the
Company's products that comply with local standards. Additionally, international
operations are subject to other inherent risks, including:

o greater difficulty in accounts receivable collection and longer
collection periods;

o difficulties and costs of staffing and managing foreign operations;

o the impact of recessions in economies outside the United States;

o unexpected changes in regulatory requirements;

o certification requirements;

o currency fluctuations;

o reduced protection for intellectual property rights in some countries;

o potentially adverse tax consequences; and

o political and economic instability.

Any acquisitions made by the Company could disrupt its existing business
and seriously harm its financial condition. As part of the Company's ongoing
business development strategy, it considers acquisitions and strategic investments
in complementary companies, products or technologies. The Company may also evaluate
other potential transactions and transaction prospects. In the event of any purchases,
the Company could:

o issue stock that would dilute current stockholders' percentage ownership;

o incur debt;

o assume liabilities;

o incur amortization expenses related to goodwill and other intangible
assets; or

o incur large and immediate write-offs.

Operation of any acquired business and achieving the benefits of any acquisition,
involves numerous risks, including:

o problems combining the purchased operations, technologies or products;

o unanticipated costs;

o diversion of management's attention from the Company's core business;

o adverse effects on existing business relationships with suppliers and
customers;

o risks associated with entering markets in which the Company has no or
limited prior experience; and

o problems with integrating employees and potential loss of key employees,
particularly those of the purchased organizations.

The Company cannot assure that it will be able to achieve the benefits of
any such acquisition or successfully integrate any acquired businesses, products,
technologies or personnel, and any failure to do so could disrupt the Company's
business and seriously harm the Company's financial condition.

The Company's stock price may be volatile. An active public market for
the Company's common stock may not be sustained. The following factors could cause
the market price of the Company's common stock to fluctuate significantly:

o loss of a major corporate partner or distributor;

o significant changes or slowdowns in the funding and spending patterns of
current and prospective customers;

o the addition or departure of key personnel;

o variations in quarterly operating results;

o announcements by the Company or its competitors of significant contracts,
new technologies, new products or product enhancements;

o failure to meet the Company's product milestones;

o acquisitions, distribution partnerships, joint ventures or capital
commitments;

o changes in financial estimates by securities analysts;

o sales of common stock or other securities in the future;

o changes in market valuations of water purification technology companies;

o fluctuations in overall stock market prices and volumes.

In addition, the stock market in general has experienced extreme price
and volume fluctuations that have often been unrelated or disproportionate to the
operating performance of individual companies. These broad market and industry
factors may materially adversely affect the market price of the Company's common
stock, regardless of its actual operating performance. In the past, following periods
of volatility in the market price of a company's securities, securities class action
litigation has often been instituted against such companies. Such litigation, if
instituted, could result in substantial costs and a diversion of management's attention
and resources.

The Company's business is subject to governmental regulations and licensing
requirements. The water purification and disinfection industry is subject to local,
state and federal regulations and licensing requirements governing water quality
and the sale of water purification and disinfection products. Although the Company
makes every effort to comply with such regulations and licensing requirements,
doing so can be an expensive, time consuming process. Moreover, laws and regulations
may change. A change in laws, regulations or licensing requirements may require the
Company to incur additional, unexpected expenses.

Item 2. Description of Property.

The Company leases its principal offices at 28163 U.S. 19 North, Suite 302
Clearwater, Florida, 33761, pursuant to a three (3) year Executive Suite Lease
Agreement between Klein & Heuchan, Inc. and the Company dated July 18, 2000.

The Company owns no real property.

Item 3. Legal Proceedings.

On April 12, 2001, the Company filed a declaratory judgment action in the
Circuit Court of Pinellas County, Florida against IMS and ETI-H2O. The lawsuit
seeks a judicial declaration regarding certain license agreements actually or
purportedly entered into between the parties. Specifically, the Company seeks a

judicial ruling confirming that a purported Manufacturing, Licensing and Distribution
Agreement dated March 26, 2000 between the Company, IMS and ETI-H2O did not constitute
a binding contract. Additionally, the lawsuit seeks to confirm (i) that the Standard
Manufacturing Agreements dated November 30, 1998 and September 17, 1999 between
the Company and ETI-H2O do not grant ETI-H2O exclusive, worldwide manufacturing
rights for the Company's Axenohl product line, and that (ii) the November 24, 1999
License Agreement between IMS and the Company does not transfer exclusive, worldwide
distribution and marketing rights for Axenohl to IMS.

Item 4. Submission of Matters to a Vote of Security Holders.

NONE

PART II

Item 5. Market for Common Equity and Related Stockholder Matters.

SUMMARY OF QUARTERLY HIGH & LOW PRICE OF COMMON STOCK
1999-2000

QUARTER HIGH BID LOW BID

1st Quarter 1999 0.20 0.05

2nd Quarter 1999 0.20 0.0425

3rd Quarter 1999 0.13 0.055

4th Quarter 1999 0.0825 0.07

1st Quarter 2000 0.42 0.19

2nd Quarter 2000 0.58 0.18

3rd Quarter 2000 0.26 0.17

4th Quarter 2000 0.19 0.13

(1) The above table is based on Over-The-Counter quotations. These quotations
reflect inter-dealer prices, without retail mark-up, markdown or
commissions, and may not represent actual transaction.

(2) All historical data was obtained from OTC:BB web site or the Pink Sheets
web site.

As of April 6, 2001, there were 526 owners of record of the Company's
common stock.

The Company is just emerging from a developmental stage and as such has
not declared a dividend to date. As the Company's royalty agreements come into
play during the last quarter of year 2001, the Company hopes to become profitable
for the first time. The nature of the Company's products dictates a continued and
increasing research and development expenditure to expand the number of markets.
Additionally, the patent expense for numerous international patents and the
certification process (EPA, FDA, USDA) in numerous countries will continue to tax
revenues. Management does not expect to declare dividends until at least the last
quarter of 2002, if ever.

Recent Sales Of Unregistered Securities.

The following table sets forth information with respect to sales by the
Company of its securities during the past three years without registration under
the Securities Act of 1933. The table sets forth the name of each purchaser, the
amount of securities sold, the consideration received by the Company and the date
of the transaction.

As indicated in the following table by the symbol "+", with respect to sales
of 2,729,999 shares of stock for an aggregate consideration of $221,000, the Company
retained Jack Augsback & Company (an affiliate of Angel Investments, LLC) as
placement agent, for which the Company paid compensation of $28,000.

As indicated in the table by the symbol "&", the Company has issued
223,530 shares of common stock to five independent contractors in exchange for
services rendered on behalf of the Company. In addition, as indicated in the table
by the notation "Settlement," the Company issued an aggregate of 568,776 shares of
common stock to four persons in settlement of contractual disputes. Finally, in
December 2000, the Company issued 1,908,000 shares of common stock to five persons
in connection with the acquisition of EHPCI, Ltd. These transactions are indicated
in the table by the notation "Acquisition."

All other transactions described in the table were sales of the Company's
common stock for cash, none of which were underwritten. None of the sales involved
a public offering.

All sales were made to persons the Company believes to be accredited investors
(indicated in the table by the symbol "*"), or to unaccredited investors the Company
believes are sophisticated enough to understand the merits and risks of purchasing
the Company's stock (indicated in the table by the symbol "**").

Except as described in the next paragraph, all sales described in the table
were made in reliance on the exemption provided by Rule 504. In connection with

such transactions, the Company complied with the manner of offering restrictions
of Rule 502(c), and as required by Rule 502(d), the Company exercised reasonable
care to assure that the purchasers of the securities were not underwriters.

Certain recent transactions described in the table were made in reliance
on the exemption provided by Rule 506. Such transactions are indicated in the table
by the notation"506." In connection with such transactions, the Company limited
sales of stock to purchasers who are accredited investors or are unaccredited investors
the Company believes are sophisticated enough to understand the merits and risks
of purchasing the Company's stock. Further, the Company complied with the information
requirements of Rule 502(b), the manner of offering restrictions of Rule 502(c),
and as required by Rule 502(d), the Company exercised reasonable care to assure
that the purchasers of the securities were not underwriters.

Name No. Shares Price Date Notes

Thomas H. and Peggy Pearson 253,333 $38,000 7/7/98 *

Lillie Lee Lucas 227,272 $22,727 7/7/98 *
Kristina C. Burgess

Lillie Lee Lucas 113,626 $11,362 7/7/98 *
Bert Lucas

C & P Trust Company 61,500 $9,875 7/7/98 *

Jeff P. Hower 300,000 $15,000 7/7/98 *

Will Corder 300,000 $15,000 7/7/98 *

Colin B. Campbell 55,555 55,555 7/7/98 *

David and Victoria Campbell 55,555 $3,000 7/7/98 *

Coffee House Investment Club 7,777 $500 7/7/98 *

Israel Santiago 21,429 $3,000 7/7/98 *

Robert Hall 50,000 $5,000 7/7/98 **&

Jeff P. Hower 250,000 $20,000 8/14/98 *

John Dickens 250,000 $20,000 8/14/98 *

Karen Lynn Stromsted 10,000 $1,000 10/14/98 *

Thor Stromsted 100,000 $5,000 10/14/98 **&

William H. Neal 10,000 $1,000 10/14/98 *

George Duren 112,500 $5,000 10/14/98 **

Jeff P. Hower 250,000 $10,000 10/14/98 *

John Dickens 250,000 $10,000 10/14/98 *

Will Corder 250,000 $10,000 10/14/98 *

Fairway Associates 300,000 $13,500 11/4/98 *

Fairway Associates 200,000 $9,500 11/13/98 *

David Campbell 16,666 $1,000 11/13/98 *

Kristina C. Burgess 50,000 $3,500 11/13/98 *

Bert Lucas 50,000 $3,500 11/13/98 **

Fairway Associates 200,000 $9,500 11/20/98 *

Fairway Associates 250,000 $13,500 12/4/98 *

Fairway Associates 300,000 $9,000 12/23/98 *

Fairway Associates 300,000 $9,000 1/6/99 *

Fairway Associates 250,000 $9,325 1/7/99 *

Fairway Associates 250,000 $12,500 1/15/99 *

Fairway Associates 300,000 $15,000 1/20/99 *

Amram Rothman 126,984 $10,000 2/19/99 *

Fairway Associates 250,000 $23,750 1/27/99 *

Robert Zola 19,230 $2,500 1/27/99 **

Richard Lynch 300,000 $21,000 1/27/99 *

Jeff P. Hower 300,000 $21,000 1/27/99 *

John Filak 110,000 $11,000 1/27/99 *

Kristina C. Burgess 10,000 $1,350 1/27/99 *

Bert R. Lucas 10,000 $1,350 1/27/99 *

Fairway Associates 300,000 $17,500 2/19/99 *

Amram Rothman 126,984 $10,000 2/19/99 *

Robert W. Geiger 20,000 $1,000 2/23/99 *

Fairway Associates 275,000 $12,375 3/1/99 *

Amram Rothman 210,526 $10,000 3/19/99 *

Fairway Associates 400,000 $14,000 3/27/99 *

Fairway Associates 175,000 $6,500 4/5/99 *

Amram Rothman 266,667 $10,000 4/12/99 *

Amram Rothman 439,216 $20,000 5/11/99 *

Sholem Liebenthal 246,184 $10,000 5/11/99 *

Amram Rothman 125,000 $10,000 5/25/99 *

Sholem Liebenthal 129,032 $10,000 5/25/99 *

Mary and John Bagnato 100,000 $10,000 5/25/99 *

Steven R. Haligas Trust 35,000 $1,000 6/6/99 *

Sholem Liebenthal 106,667 $10,000 6/21/99 *

Amram Rothman 64,829 $6,077 6/21/99 *

Maria Staymates 145,000 $12,325 7/2/99 *

Doyal F. Plank Jr. 30,000 $2,250 7/2/99 *

William W. Knicley 25,000 $2,125 7/2/99 *

David Campbell 33,333 $3,000 7/2/99 *

Sholem Liebenthal 140,351 $10,000 8/11/99 *

Sholem Liebenthal 135,593 $10,000 8/26/99 *

Edmund D. Wright 25,000 $1,000 8/26/99 **

Waterford Enterprises, LLC 320,000 $21,000 9/10/99 *

Manoj Associates, LLC 250,000 $13,750 9/14/99 *

Manoj Associates, LLC 300,000 $15,000 9/23/99 *

HLKT Holding, LLC 400,000 $20,000 9/27/99 *

Manoj Associates, LLC 300,000 $11,250 10/5/99 *

Manoj Associates, LLC 350,000 $14,000 10/12/99 *

Manoj Associates, LLC 300,000 $9,000 10/21/99 *

Manoj Associates, LLC 300,000 $11,250 10/29/99 *

Manoj Associates, LLC 300,000 $15,000 11/4/99 *

Amram Rothman 253,968 $10,000 11/10/99 *

Manoj Associates, LLC 250,000 $10,000 11/12/99 *

Manoj Associates, LLC 250,000 $10,000 11/19/99 *

HLKT Holding, LLC 231,884 $10,000 11/22/99 *

Sholem Liebenthal 231,884 $10,000 11/22/99 *

Manoj Associates, LLC 330,000 $13,860 11/30/99 *

Manoj Associates, LLC 175,000 $16,188 12/17/99 *

Nancy Lutz 100,000 $10,000 12/21/99 *

Sholem Liebenthal 110,942 $10,000 12/21/99 *

HLKT Holding, LLC 160,321 $10,000 12/21/99 *

Manoj Associates, LLC 140,000 $12,600 1/4/00 *

Manoj Associates, LLC 175,000 $15,750 1/7/00 *

Manoj Associates, LLC 150,000 $13,500 1/28/00 *

HLKT Holding, LLC 300,000 $10,000 1/28/00 *

HLKT Holding, LLC 50,000 $1,500 3/1/00 *

Sr. Federico Rodriguez 416,666 $50,000 4/20/00 *

Mr. Bert Lucas 200,000 $20,000 4/20/00 **

Ms. Kristina Burgess 200,000 $20,000 4/20/00 *

David & Victoria Campbell 200,000 $20,000 4/20/00 *

Mr. Robert Stahlschmidt 225,000 $27,000 4/20/00 *

Mr. Del Welker 200,000 $18,182 4/20/00 *

Mr. Peter S. Gibson 200,000 $20,000 4/20/00 *

Nancy Lutz 100,000 $10,000 4/20/00 *

Mr. Will Corder 500,000 $30,000 4/20/00 *

Manoj Associates, LLC 100,000 $15,000 4/20/00 *

HLKT Holding, LLC 50,000 $13,500 4/22/00 *

Manoj Associates, LLC 120,000 $15,000 5/8/00 *

Manoj Associates, LLC 160,000 $14,400 5/12/00 *

Mr. Thomas Sweeney 100,000 $12,000 5/13/00 *

Mr. Gary Wiegele 24,111 $4,340 5/13/00 *

Mr. Craig Sheffield 150,000 $29,000 5/13/00 *

Mr. Jeff Hower 800,000 $32,889 5/13/00 *

Mr. John Dickens 200,000 $20,000 5/13/00 *

The Chelverton Fund 2,533,333 $211,000 6/7/00 *

Mr. Jeff Hower 550,000 $22,611 6/7/00 *

Mr. John Dickens 300,000 $20,000 6/7/00 *

Mr. James Grandquest 46,666 $4,666 6/7/00 *

Mr. Del Welker 20,000 $1,818 6/7/00 *

William Neal 10,000 $1,000 6/7/00 *

Joanna Urchism 50,000 $5,000 6/7/00 *+

Joanna Urchism 50,000 $5,000 6/28/00 *+

Thomas Sidoti 50,000 $5,000 6/28/00 *+

Augsback & Associates 200,000 $18,000 7/13/00 *+

Manoj Associates, LLC 100,000 $10,000 7/19/00 *

Beverly Lewis 80,000 $8,000 7/20/00 +

Philip Lewis 290,000 $29,000 7/20/00 *+

Jon W. & M. Catherine Urchisin 50,000 $5,000 7/27/00 *+

Manoj Associates, LLC 120,000 $12,000 8/2/00 *

Thomas Sidoti 50,000 $5,000 8/3/00 *+

Jack Augsback 30,000 $3,000 8/3/00 *+

Tammy Augsback 50,000 $5,000 8/3/00 *+

Dr. Stephen Mazer 100,000 $10,000 8/3/00 *+

Thor Stromsted 150,000 $7,500 8/3/00 **

Manoj Associates, LLC 125,000 $11,250 8/11/00 *

Jack Augsback 100,000 $10,000 8/16/00 *

Betty Lou Brinkman 70,000 $7,000 8/17/00 *+

Gerald & Geraldine Bargonzi 50,000 $5,000 8/17/00 *+

Robert & Ellen Mulcahey 30,000 $3,000 8/17/00 *+

Betty Lou Brinkman 70,000 $7,000 9/3/00 *+

Tammy Augsback 70,000 $7,000 9/3/00 *+

Dr. Stephen Mazer 100,000 $10,000 9/3/00 *+

Jack Augsback 110,000 $13,200 9/19/00 *+

The Chelverton Fund, Ltd. 414,583 $49,750 9/28/00 *+

The Chelverton Fund, Ltd. 927,083 $111,249 10/6/00 *

The Chelverton Fund, Ltd. 75,000 $14,000 10/16/00 *

The Chelverton Fund, Ltd. 133,333 $6,666 11/9/00 *

Murdock Capital Partners(BVI) Ltd. 50,000 $5,000 12/8/00 *

John Mercier 43,776 Settlement 12/8/00 **

Daniel Boatman 11,765 $1,000 12/8/00 **

Carrie Pluto 11,765 $1,000 12/8/00 **

Mrs. Justina Alexander 56,250 Acquisition 12/14/00 *

Ernest Sydney Garvey 56,250 Acquisition 12/14/00 *

Richard Michael Goodall 384,750 Acquisition 12/14/00 *

Nearco Trust Co (Jersey) Ltd. 321,750 Acquisition 12/14/00 *

Mrs. Hillary Margaret Reid 1,089,000 Acquisition 12/14/00 *

Murdock Capital 545,454 $30,000 12/14/00 *

Beverly Lewis 363,636 $20,000 12/14/00 *

The Chelverton Fund, Ltd. 360,000 $18,000 12/14/00 *

Manoj Associates, LLC 200,000 $14,000 12/14/00 *

Orienstar Financial, Ltd. 1,081,081 $50,000 12/14/00 *

Manoj Associates, LLC 1,800,000 $85,000 12/14/00 *

Manoj Associates, LLC 200,000 $12,000 12/28/00 *

H. Theodore Quale 20,000 $1,900 1/31/01 **506

Kristina C. Burgess 427,971 $53,420 2/6/01 *506

Bert R. Lucas 100,000 $12,482 2/6/01 *506

Kelly R. McGaughey 234,000 $11,700 3/16/01 *506

Paul O. Wright 206,000 $10,300 3/16/01 **506

Mr. Jeff P. Hower 275,000 Settlement 3/7/01 *506

Mr. John E. Dickens 125,000 Settlement 3/7/01 *506

Mr. Will Corder 125,000 Settlement 3/7/01 *506

The Chelverton Fund, Ltd. 990,100 $50,000 4/4/01 *506

* Accredited investor
** Unaccredited, sophisticated investor
+ Commission paid
& Issued for services
506 Reliance on Rule 506 (all others Rule 504)

Item 6. Management's Discussion and Analysis or Plan of Operation.

The following discussion should be read in conjunction with the financial data
appearing elsewhere in this report.

Results Of Operations

Although the Company has been in existence for a number of years, management's
efforts to develop the Company's business have not yet resulted in generation of
significant revenues. To date, management's efforts have focused on developing licensing
relationships and promoting and conducting research and development to demonstrate
the feasibility and efficacy of the Company's products. Until potential customers
are convinced of the viability of the Company's technology, it is unlikely that
the Company will generate significant revenue. The following discussion of the
Company`s historical financial results should be read against that background.

Fiscal 2000 vs. Fiscal 1999

At this stage of its development, the Company's revenues consist of sales
of products incidental to research and testing activities.. For the year ended
December 31, 2000, revenues decreased from $34,836 to $12,588, a decrease of $22,248,
or 63.9%. The decrease was a result of declining consumption of Company products
at test sites. For the same period, cost of sales increased from $35,301 to $59,190,
an increase of 67.7%. Management believes that a change in product mix caused the
increase in cost of sales. Nevertheless, because of the small sales volume and its
dependence on the type of testing conducted in a particular period, these results
are not indicative of the sales, cost of sales or margins that the Company may
attain if its sales goals are achieved.

The largest component of the Company's operating expenses is personal services,
which consist of salaries, payroll taxes and other employment-related costs. Personal
services expense increased from 1999 to 2000 by $45,830, or 20.1%. The increase
resulted from payment to the Company's officers of an increased percentage their
stated compensation rates over 1999. Another significant component of the Company's
operating expenses is professional services. This component consists of legal and
accounting fees. Professional services expense increased from 1999 to 2000 by $131,445,
or 135.1%. The increase in professional services expense resulted from (i) legal
fees associated with the Company's patent activities and its preparation of filings
required by the securities laws, and (ii) accounting fees associated with preparing
the audited financial statements contained in its securities filings.

The Company's research and development expense decreased by $60,658, while
its marketing expense increased by $83,851. These changes reflect the completion
of much of the research underlying the Company's products and the change of its

focus to promoting, rather than developing, its basic product lines.

The Company's overall operating expenses increased from 1999 ($639,202)
to 2000 ($809,897). This increase resulted from substantial increases in professional
service fees, marketing expenses and other expenses arising from the Company's increased
marketing efforts as well as its efforts to register its common stock under the
Securities Exchange Act of 1934.

Interest expense decreased from $153,470 to $16,433 as a result of the
Company's extensive use of debt financing in 1999, much of which was converted to
equity at December 31, 1999.

Future Periods

The Company's expenses, other than rent and personnel costs, are variable
in nature. The Company's personnel costs have been reduced to the costs of its two
executive officers. In fact, management expects that personnel costs will increase
substantially in 2001 and future years as the Company expands its marketing efforts.
Most of the Company's other operating expenses, however, are expected to decline
with time. Management believes that the level of professional fees paid by the Company
in 1999 and 2000 will decline substantially. It will also require less testing to
establish the efficacy of its products as its current research and development
matures and as its products are exposed to the marketplace through the efforts of
its licensees. Management expects to see the results of these efforts beginning in 2001.

Liquidity and Capital Resources

General

The Company's operating requirements have regularly exceeded its cash flow
from operations as it continues to engage in testing and development of its products.
The Company's cash used in operating activities for 2000 was $853,719, compared to
$572,566 for 1999. The Company also invested in assets of approximately $125,447
in 2000, as compared to $21,903 in 1999. The resulting cash shortfall was financed
through the issuance of debt instruments, in 1999, and through the private offering
of common stock in 2000.

Based upon the Company's current plans, the Company anticipates that it
will need to seek additional financing. The Company has engaged in a number of
tests and demonstrations and has entered into license agreements with entities
for the distribution of its products. These licensing relationships are in their
early stages, however, and none of them have yet resulted in the payment of any
royalties or other amounts to the Company. It is difficult to predict what revenue
stream, if any, they will generate.

The Company does not expect its royalty stream to be sufficient to cover
costs of operations in the near future. The Company expects that it will continue
to be required to raise capital to fund operations at least through the second quarter
of 2001. The Company will attempt to raise this capital by borrowing, but no lender
has issued a binding commitment to the Company. Therefore, the Company expects to
engage in one or more private placements of common stock to fund its operating needs.
The Company has engaged in discussions with several investment banking firms who
have expressed interest in assisting the Company in such a private offering. Management
is confident that private equity financing will be available to fund it until revenues
from licensing operations are sufficient to fund operations.

Capital Expenditures

Management does not expect to incur any significant capital expenditures
in the foreseeable future.

Staffing

The Company must increase its work force. Currently, the Company has two
full-time employees. The Company's marketing plan does not call for building a sale
force to sell to end-users but instead to license the technology to market segment
leaders with existing sales forces. The Company will train these sales forces to
sell the Company's products and to provide technical assistance through quarterly
service to the systems. Nevertheless, the Company requires an increased sales force
to sell technology licensing agreements. Management expects to add five employees
in 2001. The expected cost of these additional employees is $250,000 in 2001.

Item 7. Financial Statements.

CONTENTS

Page

INDEPENDENT AUDITORS' REPORT 52

FINANCIAL STATEMENTS:

Consolidated Balance Sheet 53

Consolidated Statements of Operations 54

Consolidated Statements of Changes in Stockholders' Deficit 55

Consolidated Statements of Cash Flows 56

Notes to Consolidated Financial Statements 57

INDEPENDENT AUDITORS' REPORT

Board of Directors and Stockholders
NVID International, Inc. and Subsidiary
Sarasota, Florida

We have audited the accompanying consolidated balance sheet of NVID International,
Inc. and Subsidiaries (the Company) as of December 31, 2000, and the related consolidated
statements of operations, changes in stockholders' deficit, and cash flows for the
years ended December 31, 2000 and 1999. These consolidated financial statements are
the responsibility of the Company's management. Our responsibility is to express an
opinion on these consolidated financial statements based on our audits. We did not
audit the financial statements of EHPC Ionisation, Ltd., a London based subsidiary
acquired in December 2000. EHPC Ionisation Ltd.'s financial statements reflect total
assets of $12,538 as of December 31, 2000. Those statements were audited by other
auditors whose report has been furnished to us and our opinion, insofar as it relates
to the amounts included for EHPC Ionisation, Ltd., is based solely on the report
of the other auditors.

We conducted our audits in accordance with auditing standards generally accepted
in the United States of America. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the consolidated financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the consolidated
financial statements. An audit also includes assessing the accounting principles
used and significant estimates made by management, as well as evaluating the overall
consolidated financial statement presentation. We believe that our audits and the
report of other auditors provide a reasonable basis for our opinion.

In our opinion, based on our audits and the report of other auditors, the consolidated
financial statements referred to above present fairly, in all material respects,
the financial position of the Company as of December 31, 2000, and the results of
its operations and its cash flows for the years ended December 31, 2000 and 1999
in conformity with accounting principles generally accepted in the United States
of America.

The accompanying consolidated financial statements have been prepared assuming that
the Company will continue as a going concern. As discussed in Note 2 to the financial
statements, the Company's significant operating losses raise substantial doubt about
its ability to continue as a going concern. Management's plans in regard to this
matter are also described in Note 2. The financial statements do not include any
adjustments that might result from the outcome of this uncertainty.

Davis, Monk & Company
April 12, 2001
Gainesville, Florida

NVID INTERNATIONAL, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEET
DECEMBER 31, 2000

ASSETS

CURRENT ASSETS
Cash $ 23,172
Accounts Receivable 22,462
Inventory 65,846
Prepaid Expenses 19,728
TOTAL CURRENT ASSETS 131,208

PROPERTY AND EQUIPMENT 37,815

OTHER ASSETS

Note Receivable from Stockholder 5,000
Patent Pending 251,954
Deposits 2,145
Goodwill 295,971

TOTAL OTHER ASSETS 555,070

TOTAL ASSETS $ 724,093
===========
LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
Accounts Payable $ 81,676
Patent Costs Payable 165,767
Accrued Salaries and Benefits 222,860
Notes Payable 35,036

TOTAL LIABILITIES 505,339

STOCKHOLDERS' EQUITY
Common Stock; 100,000,000 Shares Authorized at $.001
Par Value, 61,126,747 Shares Issued and Outstanding 61,127
Additional Paid-In Capital 6,976,008
Accumulated Deficit (6,818,381)

TOTAL STOCKHOLDERS' EQUITY 218,754

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 724,093
===========

See accompanying notes.
53

NVID INTERNATIONAL, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE YEARS ENDED DECEMBER 31, 2000 AND 1999

2000 1999

SALES $ 12,588 $ 34,836

COST OF SALES (59,190) (35,301)

GROSS PROFIT (LOSS) (46,602) (465)

OPERATING EXPENSES
Personal Services 272,036 226,206
Travel 58,292 93,839
Professional Services 228,775 97,330
Penalties and Fines 1,861 29,661
Research and Development 6,000 66,658
Rent 22,223 9,812
Depreciation and Amortization 21,379 31,319
Office Expenses 52,822 26,543
Telecommunications 23,674 14,374
Bad Debt Expense 645 --
Commissions 15,729 20,850
Marketing and Promotions 106,461 22,610

TOTAL OPERATING EXPENSES 809,897 639,202

OPERATING LOSS (856,499) (639,667)

OTHER INCOME (EXPENSE)
Interest Expense (16,433) (153,470)

NET LOSS $(872,932) $(793,137)
========= =========

BASIC NET LOSS PER SHARE $ (.01) $ (.02)
========= =========
DILUTED NET LOSS PER SHARE $ (.01) $ (.02)
========= =========

See accompanying notes.
54

NVID INTERNATIONAL, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT
FOR THE YEARS ENDED DECEMBER 31, 2000 AND 1999

ADDITIONAL
COMMON STOCK PAID-IN ACCUMULATED
SHARES AMOUNT CAPITAL DEFICIT TOTALS

Balance, January 1, 1999 48,278,886 $48,279 $4,851,618 $(5,152,312) $(252,415)

Common Stock Issued:
For Interest on Notes 20,000 20 2,680 -- 2,700
For Convertible Debt 4,704,374 4,704 259,111 -- 263,815
For Cash 7,367,563 7,368 387,080 -- 394,448
Value of Embedded
Beneficial Conversion
Features of
Convertible Debt -- -- 100,000 -- 100,000
Broker's Fees -- -- (7,604) -- (7,604)
Common Stock Cancelled (11,262,528) (11,263) 11,263 -- --

Net Loss -- -- -- (793,137) (793,137)

Balance,
December 31, 1999 49,108,295 49,108 5,604,148 (5,945,449) (292,193)

Common Stock Issued:
For Interest on Notes 50,000 50 4,950 -- 5,000
For Convertible Debt 350,000 350 39,650 -- 40,000
For Cash 12,024,980 12,025 1,063,259 -- 1,075,284
For Services 513,972 514 54,762 -- 55,276
For Business Acquisition 2,250,000 2,250 267,750 -- 270,000
Broker's Fees -- -- (61,681) -- (61,681)
Common Stock Cancelled (3,170,500) (3,170) 3,170 -- --

Net Loss -- -- -- (872,932) (872,932)

Balance, December 31, 2000 61,126,747 $ 61,127 $6,976,008 $(6,818,381) $ 218,754
========== ======== ========== =========== =========

See accompanying notes.
55

NVID INTERNATIONAL, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2000 AND 1999

2000 1999

CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss $(872,932) $(793,137)
Adjustments to Reconcile Net Loss to Net Cash
Used by Operating Activities:
Depreciation and Amortization 21,379 31,319
Bad Debt Expense 645 --
Common Stock Issued for Operating Expenses 60,277 6,515
Interest Expense From Beneficial Conversion
Feature of Convertible Debt -- 100,000
Interest Expense From Cost of Convertible Debt -- 40,500
Changes in:
Accounts Receivable 9,977 24,456
Inventory (25,767) (1,446)
Prepaid Expenses (19,728) --
Note Receivable From Shareholder -- (5,000)
Accounts Payable (5,038) (14,874)
Patent Costs Payable -- 8,689
Accrued Salaries and Benefits (23,532) 30,412
Deposits 1,000 --
NET CASH USED BY OPERATING ACTIVITIES (853,719) (572,566)

CASH FLOWS FROM INVESTING ACTIVITIES
Cash Received From Purchase of Subsidiary 364
Cash Paid For Intangible Assets - Patent (98,500) --
Cash Paid For Intangible Assets - License -- (20,000)
Purchase of Fixed Assets (27,311) (1,903)

NET CASH USED BY INVESTING ACTIVITIES (125,447) (21,903

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds From Notes and Debentures -- 259,500
Payments on Notes (28,690) (38,545)
Proceeds From Issuance of Stock (Net of
Brokers Fees of $61,681 in 2000 and
$7,604 in 1999) 1,013,602 386,844

NET CASH PROVIDED BY FINANCING ACTIVITIES 984,912 607,799

INCREASE IN CASH 5,746 13,330

CASH AT BEGINNING OF YEAR 17,426 4,096

CASH AT END OF YEAR $ 23,172 $ 17,426
======== ========

(Continued)
See accompanying notes.
56

NVID INTERNATIONAL, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2000 AND 1999
(Concluded)

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash Paid During the Year for Interest $ 11,310 $ 6,455
Noncash Investing and Financing Activities:
Accounts Payable Incurred for Intangible Assets-Patents $ 34,741 $ 31,175
Stock Issued as Payment For:
Services $ 55,277 $ --
Interest $ 5,000 $ 2,700
Debt $ 40,000 $ 260,000
Interest on Convertible Debt $ -- $ 3,815

Business Acquisition:

The Company issued 2,250,000 shares of stock to acquire a 100% share of EHPC Ionisation,
Ltd. The following assets and liabilities were acquired in the transaction:

Cash $ 364
Accounts Receivable 12,174
Goodwill 295,971
Accounts Payable (38,509)
Value of Shares Issued $270,000
========

See accompanying notes.
57

NVID INTERNATIONAL, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2000 AND 1999

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The consolidated financial statements include those of NVID International, Inc.
(NVID) and its wholly owned subsidiaries, Aqua Bio Technologies, Inc. (Aqua Bio)
and EHPC Ionisation Ltd. (EHPCI), hereafter collectively referred to as the Company.
All significant intercompany accounts and transactions have been eliminated.

Nature of Operations

NVID was incorporated on August 26, 1984 under the state laws of Delaware. Aqua
Bio (formerly d.b.a. Superior Aqua Products) was incorporated in the state of Florida
on November 7, 1991. Effective November 14, 1994, NVID issued 18,281,500 shares
of its common stock in exchange for 100 percent of the issued and outstanding common
stock of Aqua Bio. EHPCI was incorporated in 1998 in Eastcote, Middlesex United Kingdom.
Effective December 12, 2000, NVID issued 2,250,000 of its common stock in exchange
for 100 percent of the issued and outstanding common stock of EHPCI.

The Company is in the business of marketing and distributing electronic water purification
systems. The system contains specially designed electrodes inside an "ion chamber".
A safe, low, electronic charge is sent to the electrodes by a solid state control
unit. This produces positive charged atoms called "ions" of copper and silver, which
are concentrated to 60 ppb and injected into the process water where they attach
and kill algae, bacteria, fungus, yeast, etc. The charged, dead microorganisms attach,
forming larger particles which are removed by the existing filtration system. The
system use is directed towards residential, commercial, industrial, and municipal
applications.

The Company maintains corporate offices in Clearwater and Sarasota, Florida.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting
principles requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of
revenues and expenses during the reporting period. Actual results could differ from
those estimates.

Cash Equivalents

The Company considers all highly liquid investments with an original maturity of
three months or less when purchased to be cash equivalents.

Accounts Receivable

Accounts receivable are reported at net realizable value. There was no allowance
for doubtful accounts at December 31, 2000 or 1999 since all receivables are deemed
fully collectible. There are no identifiable concentrations of credit risk related
to receivables.

NVID INTERNATIONAL, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2000 AND 1999

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Inventory

The inventory of product held for sale is carried at the lower of cost or market
value using the first-in-first-out method.

Property and Equipment

Property and equipment is recorded at its acquisition cost. Depreciation is provided
using the straight-line method over the estimated useful lives of five to seven years.

Maintenance and repairs of property and equipment that do not improve or extend
the life of the respective assets are charged to expense as incurred. Major renewals
and betterments are treated as capital expenditures and depreciated accordingly.

When assets are retired or otherwise disposed of, the cost of the assets and the
related accumulated depreciation are removed from the accounts with any gain or
loss on disposition reflected in the statement of operations.

Intangible Assets

Intangible assets are stated at cost less accumulated amortization. Amortization
of the license agreement is computed using the straight-line method over the estimated
useful life of five years. Amortization of patent costs will begin after the patents
are issued.

Revenue and Cost Recognition

The Company utilizes the accrual method of accounting whereby revenue is recognized
when earned and expenses are recognized when incurred. For license fees, the earnings
are recognized on a straight-line basis over the term of the license agreement.
For product sales, the Company and the customer agree to a product test period and
goals. When testing standards are met, the customer is required to purchase the
equipment and the sale transaction is recorded. Product testing and marketing costs
are expensed as incurred.

Income Taxes

No provision for taxes has been made due to cumulative operating losses at December
31, 2000. The Company has net operating loss carryforwards of approximately $4,600,000
which will expire in 2009 through 2014. No tax benefit has been reported in the
financial statements and the potential tax benefits of the loss carryforwards are
offset by a valuation allowance of the same amount.

Stock Issued for Goods and Services

When common stock is issued as payment for goods and services, the transaction is
measured at the fair value of the goods and services received or the fair value
of the stock issued, whichever is more clearly evident.

NVID INTERNATIONAL, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2000 AND 1999

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (concluded)

Earnings (Loss) Per Share

The computation of earnings (loss) per share of common stock is based on the weighted
average number of shares outstanding during the period.

NOTE 2 - GOING CONCERN

The Company has incurred significant cumulative net operating losses. The Company
continues to market its technologies in order to meet operational expenses. Management
expects revenue to increase significantly once patent applications are finalized
and U.S. Department of Environmental Protection (USDEP) approvals are received.
However, given the uncertainty surrounding USDEP approvals and the development stage
of much of the Company's technologies, the primary source of funding will come from
shareholders. Shareholders have continued to express support for the Company. Management
is confident that it can continue to raise sufficient financing from shareholders
until revenues begin to be received from the marketing of its products and technologies.

NOTE 3 - PROPERTY AND EQUIPMENT

Property and equipment consist of the following:

Useful
Lives 2000 1999
Manufacturing Equipment 5 years $ 8,005 $ 8,005
Trade Show Displays 7 years 13,685 13,685
Demo Units 7 years 14,617 14,617
Computer Equipment 5 years 38,449 29,067
Furniture & Fixtures 7 years 6,286 --
Self Constructed Asset in Progress -- 11,643 --

Total 92,685 65,374

Less Accumulated Depreciation (54,870) (43,491)

Property and Equipment, Net $ 37,815 $ 21,883

Depreciation expense for the years ended December 31, 2000 and 1999 was $11,379
and $11,319 respectively.

NVID INTERNATIONAL, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2000 AND 1999

NOTE 4 - INTANGIBLE ASSETS

Intangible assets consist of the following:

2000 1999
Patents Pending $ 251,954 $117,713
Less Accumulated Amortization -- --
Patents Pending, Net $ 251,954 $117,713
========== =========
License Agreement $ 40,000 $ 40,000
Less Accumulated Amortization (40,000) (30,000)
License Agreement, Net $ -- $ 10,000
========== =========

Patent pending costs are being incurred to secure the patent on Axenol. The patent
was received in March 2001. The costs incurred include professional fees of the
Company's patent attorneys and the costs of product testing.

2000 1999

Patent Attorney Fees (See Note 5) $ 35,741 $ 31,175
Patent Attorney Fees Paid in Cash 98,500 --

Costs at January 1 117,713 86,538

Costs at December 31 $ 251,954 $117,713
========== =========
Goodwill $ 295,971 $ --
Less Accumulated Amortization -- --

Goodwill, Net $ 295,971 $ --
========== =========

The license agreement gives the Company the rights to commercialize the random metering
system (RMS). RMS products incorporate technologies to treat large volumes of water.
The agreement has an initial term of two years with provisions for continuous renewal.
Because management had no basis for determining whether the agreement would be renewed,
the license agreement was amortized over the initial term of two years.

Amortization expense for the years ended December 31, 2000 and 1999 was $10,000
and $20,000 respectively.

Goodwill associated with the acquisition of EHPCI in December, 2000 will be amortized
in future years on a straight line basis over a life of 40 years.

NVID INTERNATIONAL, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2000 AND 1999

NOTE 5 - PATENT COSTS PAYABLE AND STOCK WARRANT

The Company has retained the services of a patent attorney (the attorney) since
1995 to whom it owes $165,767 and $130,026 at December 31, 2000 and 1999, respectively.
Of these amounts, $139,453 and $103,712 were capitalized as patent pending at December
31, 2000 and 1999, respectively. The balance was expensed as professional fees since
the related projects are no longer active.

At December 30, 1998, the Company issued a warrant agreement providing the attorney
the option to purchase 750,000 shares of stock at an exercise price of $.10 per
share. The warrant exercise period started on December 31, 1999 and runs through
December 30, 2003. The warrant agreement gives the attorney the right to apply any
portion of the outstanding balance owed by the Company for payment of the exercise
price. The value of the warrant was recorded as additional paid-in capital and
professional fees at the date of issuance.

The fair value of the option was estimated using the Black-Scholes option pricing
model with the following assumptions: risk free interest rate of 6%; 0% dividend
yield; a 5 year expected life; and volatility of 170%.

NOTE 6 - NET LOSS PER SHARE

Net Loss Shares Per Share
2000 (Numerator) (Denominator) Amount
Basic Net Loss per Share:
Net Loss Attributable to
Common Stockholders $(872,932) 61,126,747 $ (.01)
========== ========== ========
Diluted Net Loss per Share:
Net Loss Attributable to
Common Stockholders $(872,932) 61,126,747 $ (.01)
========== ========== ========
1999
Basic Net Loss per Share:
Net Loss Attributable to
Common Stockholders $(793,137) 48,693,590 $ (.02)
========== ========== ========
Diluted Net Loss per Share:
Net Loss Attributable to
Common Stockholders $(793,137) 48,693,590 $ (.02)
========== ========== ========

The effect of shares issuable pursuant to the exercise of warrants and the conversion
of debentures has been excluded from the computation of Dilutive Net Loss per Share
because the inclusion would be antidilutive.

NOTE 7 - NOTES PAYABLE

Notes payable were due in June of 1999. However, the notes included the option for
the holders to extend the repayment terms or to require issuance of the Company's
stock at the date of maturity. The notes have been extended without a specified
due date. Interest accrues at 20%.

NVID INTERNATIONAL, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2000 AND 1999

NOTE 8 - PENALTIES AND FINES

For the year ended December 31, 2000 and 1999, amounts reported as penalties and
fines consist primarily of assessments from the Internal Revenue Service for late
payment of payroll taxes.

NOTE 9 - EQUITY TRANSACTIONS

The Company issues common stock 1) for cash, 2) in exchange for goods or services
received, and 3) for debt conversions. Common stock was issued for convertible debt
in accordance with the terms of the debt instrument.

The Company canceled 3,170,500 shares of stock in accordance with a final judgment
from the Securities and Exchange Commission. The shareholder was a former director
of the Company.

NOTE 10 - PURCHASE OF EHPC IONISATION LIMITED

In December 2000, the Company completed the purchase of EHPC Ionisation Limited
(EHPCI), a privately held water purification company organized under the laws of
England. NVID acquired all of the outstanding capital stock of EHPCI for a total
purchase price of 3,000,000 shares of NVID common stock. The acquisition was accounted
for using the purchase method of accounting. EHPCI's operations have not been included
in the consolidated financial statements since the operations for the period from acquisition
through December 31, 2000 were insignificant.

The following presents the assets acquired and liabilities assumed:

Cash $ 364
Accounts Receivable 12,174
Goodwill 295,971
Current Liabilities (38,509)
Total Acquisition Cost $270,000
========

The Stock Purchase Agreement provides that 75,000 shares of the total purchase price
will be held in escrow for a period of six months following the execution of the
agreement. The release of those shares is contingent on the actual amount of liabilities
assumed. The number of shares to be released from escrow to the former shareholders
of EHPCI will be 75,000 if no liabilities are determined to have existed at the
acquisition date other than those listed above. The number of shares to be released
from escrow will be reduced proportionately for liabilities assumed which were not
identified at the acquisition date. The total acquisition cost and the goodwill
listed above include only those shares issued through December 31, 2000. The value
of any additional shares to be issued in connection with this acquisition will increase
the recorded amount of goodwill.

NVID INTERNATIONAL, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2000 AND 1999

NOTE 10 - PURCHASE OF EHPC IONISATION LIMITED (concluded)

The following (unaudited) proforma consolidated results of operations have been
prepared as if the acquisition of EHPCI had occurred at January 1, 1999.

December December
31, 2000 31, 1999
Sales $ 12,588 $ 79,836
Net (Loss) (898,068) (791,590)
Net Income Per Share - Basic (.01) (.02)
Net Income Per Share - Diluted (.01) (.02)

The proforma information is presented for informational purposes only and is not
necessarily indicative of the results of operations that actually would have been
achieved had the acquisition been consummated as of that time, nor is it intended
to be a projection of future results.

NOTE 11 - WARRANTS

During the year ended December 31, 2000, the board of directors approved the issuance
of warrants to purchase an aggregate of 3,453,333 shares of the Company's common
stock in conjunction with the sale of the same number of shares of common stock.
Such warrants are exercisable at $.10 per share, are immediately exercisable, and
expire at various times through August, 2002.

Certain shareholders exercised the warrants at the same time as they purchased the
shares with which the warrants were issued. The Company issued 270,000 shares of
common stock for an aggregate of $27,000 upon the exercise of these warrants. The
remaining 3,183,333 warrants issued with the 2000 stock purchase transactions remain
outstanding at December 31, 2000.

During 1998, the Company issued warrants to purchase 750,000 shares of the Company's
common stock to an attorney in exchange for services. Such issuance was accounted
for under Financial Accounting Standards Board Statement No. 123 using the Black-Scholes
option pricing model, which resulted in the recording of $34,875 in compensation
cost during the year ended December 31, 1998.

A summary of warrant activity for 2000 and 1999 is as follows:

Weighted Weighted
Number Average Average
of Exercise Warrants Exercise
Warrants Price Exercisable Price
Outstanding,
December 31, 1998 750,000 $ .10 750,000 $ 10
Granted --
Exercised --

NVID INTERNATIONAL, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2000 AND 1999

NOTE 11 - WARRANTS (concluded)

Outstanding,
December 31, 1999 750,000 $ .10 750,000 $ 10
Granted 3,453,333 .10
Exercised (270,000) .10

Outstanding,
December 31, 2000 3,933,333 $ .10 3,933,333 $ 10

At December 31, 2000, the range of warrant prices for shares under warrants and
the weighted average remaining contractual life is as follows:

Warrants Outstanding Warrants Exercisable

Weighted
Weighted Average Weighted
Range of Average Remaining Average
Warrant Number of Exercise Contractual Number Exercise
Exercise Price Warrants Price Life Exercisable Price

$ .10 3,933,333 $ .10 1.87 yrs 3,933,333 $ 10

NOTE 12 - RELATED PARTY TRANSACTIONS

From time to time management enters into contracts with shareholders for professional
services. Payments are made in either cash, or by the issuance of stock. During
the year, the Company incurred approximately $6,000 in expenses in contracts with
related parties.

During the year ended December 31, 2000, management entered into a contract with
a related party for professional services. The Company paid approximately $6,000
for such services.

Item 8. Changes In and Disagreements With Accountants on Accounting and Financial
Disclosure.

NONE

PART III

Item 9. Directors, Executive Officers, Promoters and Control Persons; Compliance
With Section 16(a) of the Exchange Act.

The following table sets forth the names, positions with the Company and
ages of the executive officers and directors of the Company. Directors of the Company
are elected at the Company's annual meeting of stockholders and serve until their
successors are elected and qualify. Officers are elected by the Board and their
terms of office are at the Board's discretion, or until their successors are elected
and qualify.

Name Age Position Director Since

David Larson 50 President April 7, 1997
Michael Redden 52 Secretary July 10, 1997
Dr. M. Robert Edelson 65 Director November 21, 1997

David Larson. Prior to coming to the Company in July 1996, Mr. Larson
served for 4 years as the director of marketing for Pinch-A-Penny, Inc., a company
specializing in pool and patio supplies sold through 117 franchised retail stores
in Florida. Prior to joining Pinch-A-Penny, Mr. Larson held sales management positions
with a division of PPG Industries that sold disinfectants to many of the same markets
that the Company now targets. Mr. Larson started with the Company as Vice President
of Sales of Aqua Bio Technologies, Inc. and later became its President. Mr. Larson
was appointed to the Board of Directors on April 7, 1997. In June 1997, Mr. Larson
was named President of NVID, which was approved by the shareholders in November 1997.

Michael Redden. Mr. Redden was named Director of Foreign Development
for Aqua Bio Technologies, Inc. in August 1995 and has served as President for Aqua
Bio Technologies, Inc. since June 1997. Mr. Redden is currently the Company's Secretary.
Prior to working for the Company, Mr. Redden owned a yacht brokerage and charter
business on the west coast of Florida and started Caribe Star Seafood, Ltd., a
Nicaraguan-based corporation engaged in fish processing and export to the United
States and the Far East. Mr. Redden was appointed to the Company's Board of Directors
on July 10, 1997.

Dr. M. Robert Edelson. Dr. Edelson was elected to the Company's Board
of Directors on November 12, 1997, after retiring from 27 years in the water treatment
business as a transition metal chemist. He was past President of the Minnesota Environmental
Health Association, teacher of the year for the National Swimming Pool Foundation
in 1997 and is an active member on the Chemical Treatment and Process Committee
of the National Spa and Pool Institute.

Section 16(a) Beneficial Ownership Reporting Compliance

The following table sets forth the names, number of late reports, number
of late reported transactions and known failures to file a required report with
respect to required filings under Section 16(a) the Exchange Act by the Company's
officers, directors and stockholders.

Name Late Reports Transactions Known Failure

David Larson 1 Form 3 0 0

Michael J. Redden 1 Form 3 0 0

M. Robert Edelson 1 Form 3 0 0

Item 10. Executive Compensation.

Summary Compensation Table

Annual Compensation
Name and Principal Position Year Salary Bonus
($) ($)
(a) (b) (c) (d)

David Larson, CEO 1998 $76,214 $4,000
1999 $86,400 $5,000
2000 $115,666 $5,000

Michael J. Redden, CFO, Secretary 1998 $38,902 $5,000
1999 $61,258 $5,000
2000 $86,646 $5,000

Item 11. Security Ownership of Certain Beneficial Owners and Management.

The following table sets forth certain information regarding the holders
of the Company's Common Stock, par value $0.001 as of April 6, 2001 for each of
the Company's directors, and all executive officers and directors as a group. No
individual or group known to the Company holds beneficial ownership of more than
five percent of any class of the Company's voting securities. There are no arrangements
in effect which would result in a change of control of the Company. As of April 6, 2001,
there were 67,197,118 shares of Common Stock outstanding.

NVID INTERNATIONAL, INC.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS & MANAGEMENT

(1) (2) (3) (4)
Name And Amount And
Title Of Address Of And Nature Of Percent Of
Class Beneficial Beneficial Class
Owner Owner

Common David Larson, CEO, President, Director 420,000 0.63%
1792 Lago Vista Blvd.
Palm Harbor, Florida 34685

Common Michael Redden, CFO, Secretary, Director 95,000 0.14%
5153 Sandy Cove Avenue
Sarasota, Florida 34242

Common M. Robert Edelson, Director 50,000 0.07%
7400 Coventry Way
Edina, Minnesota 55439-2608

Common Directors and Officers as a Group (3 persons) 565,000 0.84%

Item 12. Certain Relationships and Related Transactions.

On May 18, 1998, the Company executed a Promissory Note in the amount of
$25,000 payable to Ms. Lilly Lee Lucas and Ms. Kristina C. Burgess, and on June 12,
1998, the Company executed a Promissory Note in the amount of $50,000 payable to Ms.
Lilly Lee Lucas, Ms. Kristina C. Burgess, and Mr. Burt Lucas (collectively, the
"Notes"). The Company has repaid the Notes. Michael Redden, a director and officer
of the Company was formerly married to Ms.Burgess. Ms. Burgess holds 841,000 shares
of the Company's common stock.

The Company owes Mr. Redden $107,063 in accrued salary.

The Company owes Mr. Larson $84,012 in accrued salary.

Item 13. Exhibits and Reports on Form 8-K.

(a) Exhibits

3.(I)a Certificate of Incorporation dated August 20, 1984 (previously filed as
Exhibit 3.(I)a to the Company's Registration Statement on Form 10-SB,
filed September 25, 2000).

3.(I)b Certificate of Amendment of Certificate of Incorporation dated March 31,
1985 (previously filed as Exhibit 3.(I)b to the Company's Registration
Statement on Form 10-SB, filed September 25, 2000).

3.(I)c Certificate of Correction of Certificate of Amendment of Certificate of
Incorporation dated October 15, 1985 (previously filed as Exhibit 3.(I)c
to the Company's Registration Statement on Form 10-SB, filed September 25, 2000).

3.(I)d Certificate for Renewal and Revival of Charter dated October 19, 1994
(previously filed as Exhibit 3.(I)d to the Company's Registration Statement
on Form 10-SB, filed September 25, 2000).

3.(I)e Certificate of Amendment of Certificate of Incorporation filed October 24,
1994 (previously filed as Exhibit 3.(I)e to the Company's Registration
Statement on Form 10-SB, filed September 25, 2000).

3.(I)f Certificate of Amendment of Certificate of Incorporation filed May 26,
1995 (previously filed as Exhibit 3.(I)f to the Company's Registration
Statement on Form 10-SB, filed September 25, 2000).

3.(I)g Certificate for Renewal and Revival of Charter dated December 9, 1996
(previously filed as Exhibit 3.(I)g to the Company's Registration Statement
on Form 10-SB, filed September 25, 2000).

3.(I)h Certificate of Amendment of Certificate of Incorporation dated February 5, 1999
(previously filed as Exhibit 3.(I)h to the Company's Registration Statement
on Form 10-SB, filed September 25, 2000).

3.(I)I Certificate of Amendment of Certificate of Incorporation dated May 12,
2000 (previously filed as Exhibit 3.(I)I to the Company's Registration
Statement on Form 10-SB, filed September 25, 2000).

3.(II) By-Laws (previously filed as Exhibit 3.(II) to the Company's Registration
Statement on Form 10-SB, filed September 25, 2000).

10.1 Distribution and License Agreement dated August 26, 1998 between EHPC
Ionization, Ltd., ABT, NVID International, Inc. & EHPC, Ltd. (previously
filed as Exhibit 10.1 to the Company's Registration Statement on Form 10-SB,
filed September 25, 2000).

10.2 Licensing Agreement dated November 10, 1998 between EHPC Ionization, Ltd.,
and Wallace & Tiernan, Ltd. (previously filed as Exhibit 10.2 to the
Company's Registration Statement on Form 10-SB, filed September 25, 2000).

10.3 Non-Exclusive License Agreement dated November 10, 1998 between EHPC Ionization,
Ltd. and Wallace & Tiernan, Ltd. (previously filed as Exhibit 10.3
to the Company's Registration Statement on Form 10-SB, filed September 25, 2000).

10.4 Supplemental Letter Agreement dated November 10, 1998 between EHPC Ionization,
Ltd. and Wallace & Tiernan, Ltd. (previously filed as Exhibit 10.4
to the Company's Registration Statement on Form 10-SB, filed September 25, 2000).

10.5 Standard Manufacturing Agreement dated November 30, 1998 between NVID
International, Inc. and ETIH20 (previously filed as Exhibit 10.5 to the
Company's Registration Statement on Form 10-SB, filed September 25, 2000).

10.6 Standard Manufacturing Agreement (Pacific Rim Countries) dated September
17, 1999 between NVID International, Inc. and ETIH20 (previously filed
as Exhibit 10.6 to the Company's Registration Statement on Form 10-SB,
filed September 25, 2000).

10.7 Royalty Letter Agreement and dated September 23, 1999 between NVID International,
Inc., ABT and Andrew B. Arata (previously filed as Exhibit 10.7 to the
Company's Registration Statement on Form 10-SB, filed September 25, 2000).

10.8 License Agreement dated November 12, 1999 between NVID International, Inc.,
EHPC Ionization, Ltd. and Innovative Medical Services (previously filed
as Exhibit 10.8 to the Company's Registration Statement on Form 10-SB,
filed September 25, 2000).

10.9 License Agreement dated November 24, 1999 between NVID International,
Inc. and Innovative Medical Services (previously filed as Exhibit 10.9
to the Company's Registration Statement on Form 10-SB, filed September 25, 2000).

21 List of Subsidiaries.

(b) Reports on Form 8-K. The Company filed no Current Reports on Form 8-K
during the fourth quarter of 2000.

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

NVID INternational, Inc.

By: /s/ David Larson
David Larson, President

Date: April 19, 2001

In accordance with the Exchange Act, this report has been signed below by
the following persons on behalf of the registrant and in the capacities and on the
dates indicated.

SIGNATURE TITLE DATE

/s/ David Larson Director, Chief April 19, 2001
David Larson Executive Officer

/s/ Michael J. Redden Director, Chief Financial April 19, 2001
Michael J. Redden and Accounting Officer

/s/ M. Robert Edelson Director April 19, 2001
M. Robert Edelson

EXHIBIT INDEX

Number Exhibit

21 List of Subsidiaries.